PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 1A PHASE 3, RANDOMIZE D, OBSERVER -BLIND ST UDY TO EVALUATE THE 
SAFETY, TOLERABILITY , AND IMMUNOGENICITY OF MULTIPLE
FORMULATION SOFTHE VACCINE CANDIDA TEBNT162b 2 AGAINST 
COVID -19 IN 
HEALTHY ADULTS 18 TH ROUGH 55 YEARS OF AG E
Study Sponsor: BioNTech
Study Conducted By: Pfizer
Study Intervention Number : PF-07302048
Study Intervention Name: BNT162b2 RNA- Based COVID -19 Vaccine
USIND Number: 19736
EudraCT Number: 2020- 002641- 42
ClinicalTrials.gov ID: [STUDY_ID_REMOVED]
Protocol Number: C4591020
Phase: 3
Short Title: A Phase 3 Study  to Evaluate the Safety , Tolerability , and Immunogenicity  of 
Multiple Formulation sof BNT162 b2 Against COVID -19 in Healthy  Adults
This document and accompanying materials contain confidential information belonging to Pfizer. Except as 
otherwise agreed to in writing, by accepting or reviewing these document s, you agree to hold this information 
in confidence and not copy or disclose it to others (except where required by applicable law) or use it for 
unauthorized purposes. In the event of any actual or suspected breach of this obligation, Pfizer must be 
promptly notified.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 2Protocol Amendment Summary of Changes Table
Document History
Document Version Date Summary and Rationale for Changes
Protocol amendment 
213 Sep 2021 The primary  immunogenicity  analy sis
demonstrated that the immune response 
elicited by  the ly ophilized formulation did 
not meet the noninferiority  criteria 
compared to the 
frozen -liquid formulation 
of BNT162b2 . As a result ,for the benefit 
of participants, updates were made to 
offer and administer an additional vaccine 
dose, using the frozen -liquid formulation ,
to participants who originally  received 
2doses of the ly ophili zed formulation of 
BNT162b2 .
Exploratory  estimand relating to 
lyophilized formulation have been 
reported (GMRs of RTU formulation to 
lyophilized formulation in SDVs 1 month 
after Dose 2)
Added 2exploratory  objectives
corresponding to administration of Dose 3 
and updated the pertinent details for the 
statistical analysis .
Updated Section 9.4.4 to add an 
exploratory  immunogenicity  objective, 
andclarified that IgG data from all 
participants in Part 1 will be used and
neutralizing titer data from a random 
sample of ~ 30age-matched participants in 
Part 1 
receiving frozen -liquid BNT162b2 
in MDVs will be used.
Following updates were in specified 
sections in response to commitment made 
to CBER concerning m yocarditis and 
pericarditis:
oUpdate d Section 2.3.1
(Risk Assessment) 
to address 
myocarditis and pericarditis safety  
concerns .
oAdded Section 8.13 for 
requirement of unplanned visit to 
capture data pertaining to 
myocarditis and pericarditis .

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 3Protocol amendment 
115Apr 2021 Removed all references to ly ophilized
MDV and added 
ability  to assess
frozen- liquid BNT162 b2 with L NP size at 
the upper end of specification and RTU
BNT162b2 in a second part of the study .
Updated corresponding objectives, 
estimands, and endpoints, including 
removal of 1 Primary  Immunogenicit y 
objective and add ition of2 new 
Exploratory  objectives in line with 
changes to formulation evaluation. 
Section 9 (Statistical Considerations) was 
updated i n line with the changes to 
objectives, estimands, and endpoints.
Updated the planned number of 
participants required for Part 2 of the 
study .
Remov
ed review of temp orary delay of 
vaccination criteria at Visit 1 in SoA and 
Section 8.11.1 (Visit 1) and revised text in 
Section 5.5 (Temporary  Delay  Criter ia).
Updated Section 2.3.1.
Addressed discrepancy  in 
Section 8.11.1 (Visit 1) describing site 
staff responsibilities for the I RT s ystem 
entries (Impala) compared with text in the 
Impala quick r eference guide, I P manual ,
and site 
blinding plan.
Updated Section 10.4.1 (Male Participant 
Reproductive Inclusion Criteria
)to correct 
a typographical error .
Original protocol 18Jan2021 N/A
This amendment incorporates all revisions to date, including amendments made at the 
request of country  health authorities and IRBs/ECs.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 4TABLE OF CONTENTS
LIST OF TABLES ................................ ................................ ................................ ..................... 8
1. PROTOCOL  SUMMARY .....................................................................................................9
1.1. Sy nopsis ....................................................................................................................9
1.2. Schema ....................................................................................................................13
1.3. Schedule of Activ ities .............................................................................................14
1.3.1. Schedule of Activities for Those Participants Who Originally  
Received Lyophilized Formulation and Accept the Offer to Receive 
Current Frozen Formulation of BNT162b2 .....................................................16
2. INTRODUCTION ...............................................................................................................18
2.1. Study  Rationale .......................................................................................................18
2.2. Backgro
und .............................................................................................................18
2.2.1. Clinical Overview .......................................................................................19
2.3. Benefit/Risk Assessment
.........................................................................................22
2.3.1. Risk Assessment
.........................................................................................24
2.3.2. Benefit Assessment .....................................................................................26
2.3.3. Overall Benefit/R isk Conclusion ................................................................26
3. OBJECTI VES, ESTIM
ANDS, AND ENDPOINTS ...........................................................26
4. STUDY DESIGN .................................................................................................................27
4.1. Overall Desig n
.........................................................................................................27
4.2. Scientific Rationale for Study  Design .....................................................................28
4.3. Justification for Dose ..............................................................................................29
4.4. End of Study  Definition ..........................................................................................29
5. STUDY POPUL ATION
................................ ................................ ................................ ......29
5.1. I nclusion Criteria .....................................................................................................29
5.2. Exclusion Criteria ....................................................................................................30
5.3. L ifesty le Considerations ..........................................................................................31
5.3.1. Contraception ..............................................................................................31
5.4. Screen Failures ........................................................................................................31
5.5. Criteria for Temporarily  Delay ing Enrollment/Randomization/Study  
Intervention Administration ................................ ................................ ...................... 32
6. STUDY INTERVENTIO N................................ ................................ ................................ ..33
6.1. Study  Intervention(s) Administered ........................................................................33

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 56.1.1. Administration ............................................................................................33
6.2. Preparation/Han dling/Storage/Accountability ........................................................34
6.2.1. Preparation and Dispensing ........................................................................35
6.3. Measures to Minimize Bias: Randomization and Blinding .....................................35
6.3.1. Allocation to Study Intervention ................................................................35
6.3.2. Blinding of Site Personnel ..........................................................................36
6.3.3. Blinding of the Sponsor
..............................................................................36
6.3.4. Breaking the Blind ......................................................................................37
6.4. Stu dy Intervention Compliance ...............................................................................37
6.5. Concomitant Therapy ..............................................................................................37
6.5.1. Prohibited During the Study .......................................................................37
6.5.2. Permitted During the Study ........................................................................38
6.6. Dose Modification ...................................................................................................38
6.7. I ntervention After the End of the Study ..................................................................38
7. DI SCONTINUATION O F STUDY 
INTERVENTION AND PARTI CIPANT 
DISCONTINUATION/WI THDRAWAL ...........................................................................39
7.1. Discontinuation of Study  Intervention ....................................................................39
7.2. Participant Discontinuation/Withdrawal From the Study .......................................39
7.2.1. Withdrawal of Consent ...............................................................................40
7.3. L ost to Follow -
up ....................................................................................................40
8. STUDY ASSESSMENTS AND PROCEDURES ...............................................................41
8.1. Efficacy  and/or Immunogenicity
 Assessments .......................................................42
8.1.1. Biological Samples .....................................................................................42
8.2. Safet y Assessments .................................................................................................43
8.2.1. Clinical Safety  Laboratory  Assessments ....................................................43
8.2.2. Electronic Diary ..........................................................................................43
8.2.2.1. G rading Scales ...........................................................................44
8.2.2.2. L ocal Reactions .........................................................................44
8.2.2.3. Sy stemic Events ........................................................................45
8.2.2.4. Fever ..........................................................................................46
8.2.2.5. Antipy retic Medication .............................................................46
8.2.3. Pregnancy  Testing ......................................................................................46

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 68.3. Adverse Events and Serious Adverse Events..........................................................47
8.3.1. Time Period and Frequency  for Collecting AE and SAE Information .......47
8.3.1.1. Reporting SAEs to Pfizer Safety ...............................................48
8.3.1.2. Recording Nonserious AEs and SAEs on the CRF
...................48
8.3.2. Method of Detecting AEs and SAEs ..........................................................48
8.3.3. Follow -up of AEs and SAEs .......................................................................48
8.3.4. Regulatory
 Reporting Requirements for SAEs ...........................................49
8.3.5. Exposure During Pregnancy  or Breastfeeding, and Occupational 
Exposure ..........................................................................................................49
8.3.5.1. Exposure During Pregnancy ......................................................49
8.3.5.2. Exposure During Breastfeeding ................................................51
8.3.5.3. Occupational Exposure .............................................................51
8.3.6. Cardiovascular and Death Events ...............................................................51
8.3.7. Disease -Related Events and/or Disease -
Related Outcomes Not 
Qualifying as AEs or SAEs ..............................................................................51
8.3.8. Adverse Events of Special Interest
.............................................................52
8.3.8.1. Lack of Efficacy ........................................................................52
8.3.9. Medical Device Deficiencies ......................................................................52
8.3.10. Medication Errors .....................................................................................52
8.4. Tre atment of Overdose ............................................................................................53
8.5. Pharmacokinetics ....................................................................................................53
8.6. Pharmacod ynamics ..................................................................................................53
8.7. Genetics ...................................................................................................................53
8.8. Biomarkers ..............................................................................................................54
8.9. I mmunogenicit y Assessments .................................................................................54
8.10. Health Economics .................................................................................................54
8.11. Study  Procedures ...................................................................................................54
8.11.1. Visit 1 
–Vaccination 1 (Day  1)................................ ................................ 54
8.11.2. Visit 2 – Vaccination 2 (19 to 23 Day s After Visit 1) .............................. 56
8.11.3. Visit 3 – 1- Month Follow -up (28 to 35 Days After Visit 2).....................59
8.11.4. Unscheduled Visits for a Grade 3 or Suspected Grade 4 Reaction .......... 59
8.12. Study  Procedures for Participants Who Accept the Offer to Receive Dose 3 ......60
8.12.1. Visit 101 
–Vaccination 3 (At Least 90 Days After Visit 2) ....................60

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 78.12.2. Visit 102 – 1- Month Follow -up (28 to 35 Day s After Visit 101) .............63
8.13. Additional Procedures for Monitoring of Potential My ocarditis or 
Peric arditis
.................................................................................................................63
9. STATI STICAL CONSI DERATIONS
................................................................................64
9.1. Estimands and Statistical Hy potheses .....................................................................64
9.1.1. Estimands ....................................................................................................64
9.1.2. Statistical Hy pothesis ..................................................................................64
9.1.3. Multiplicity  Considerations
........................................................................65
9.2. Sample Size Determination .....................................................................................65
9.3. Analy sis Sets ...........................................................................................................66
9.4. Statistical Analy ses.................................................................................................66
9.4.1. General Considerations ...............................................................................66
9.4.1.1. Analy sis for Binary  Data ...........................................................67
9.4.1.2. Analy sis for Continuous Data ...................................................67
9.4.2. Primary  Endpoint(s) ....................................................................................68
9.4.3. Secondary  Endpoint(s) ................................................................................68
9.4.4. Exploratory  Endpoint(s) .............................................................................69
9.5. I nterim Anal yses.....................................................................................................70
9.6. Data Monitoring Committee or Other Independent Oversight Committee .............70
10. SUPPORTING DOCUM ENTATION AND OPERATI ONAL 
CONSI DERATIONS ..........................................................................................................71
10.1. Appendix 1: Regulatory , Ethical, and Study  Oversight Considerations ...............71
10.1.1. Regulatory  and Ethical Considerations ....................................................71
10.1.1.1. Reporting of Safety  Issues and Serious Breaches of the 
Protocol or I CH GCP .........................................................................71
10.1.2. Financial Disclosure .................................................................................72
10.1.3. I nformed Consent Process ........................................................................72
10.1.4. Data Protection .........................................................................................73
10.1.5. Di ssemination of Clinical Study  Data ................................ ...................... 73
10.1.6. Data Qualit y Assurance ............................................................................74
10.1.7. Source Documents ................................ ................................ .................... 76
10.1.8. Study  and Site Start and Closure ................................ .............................. 76
10.1.9. Publication Policy.....................................................................................77

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 810.1.10. Sponsor’s Qualified Medical Personnel .................................................77
10.2. Appendix 2: Clinical Laboratory  Tests .................................................................78
10.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting ......................................................................79
10.3.1. Definition of AE.......................................................................................79
10.3.2. Definition of SAE
.....................................................................................80
10.3.3. Recording/Reporting and Follow
-up of AEs and/or SAEs .......................82
10.3.4. Reporting of SAEs
....................................................................................85
10.4. Appendix 4: Contraceptive Guidance ...................................................................86
10.4.1. Male Participant Reproductive Inclusion Criteria
....................................86
10.4.2. Female Participant Reprodu ctive Inclusion Criteria .................................86
10.4.3. Woman of Childbearing Potential ............................................................87
10.4.4. Contraception Methods .............................................................................88
10.5. Appendix 5: L iver Safety : Suggested Actions and Follow -up Assessments ........90
10.6. Appendix 6: Abbreviations
...................................................................................92
11. REFERENCES ..................................................................................................................95
LIST OF TABLES
Table 1.
Local Reaction Grading Scale ..................................................................44
Table 2. Systemic Event Grading Scale ..................................................................45
Table 3. Scale for Fever ..........................................................................................46
Table 4. Power Anal ysis for Noninferiorit y Assessment .......................................65

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 91.PROTOCOL SUMMARY
1.1.Synopsis
Short Title: A Phase 3 Study to Evaluate the Safety , Tolerability , and Immunogenicity  of 
Multiple Formulation of BNT162 b2 Against COVID -19 in Healthy  Adults
Rationale
A pneumonia of unknown cause detected in Wuhan, China, was first reported in 
December 2019. InJanuar y
2020, the pathogen causing this outbreak was identified as a 
novel coronavirus 2019.   The outbreak was declared a Public Health Emergency  of 
International Concern on 30 January 2020.  On 12 February  2020, the virus was officiall y 
named as severe acute re spiratory  syndrome coronavirus 2 (SARS -CoV -2), and the WHO 
officiall y named the disease caused b y SARS -CoV -2 as coronavirus disease 2019 
(COVID -19).  On 11 March 2020, the WHO upgraded the status of the COVID- 19 outbreak 
from epidemic to pandemic, which co ntinues to spread globall y at high speed.
Based on Phase 2/3 safety, immunogenicit
y, and efficacy data, BNT162b2 was shown to be 
effective and has been authorized for temporary  or emergency  usein multiple countries .
The Pfizer
-BioNTech COVID-19 v accine (also referred to as BNT162b2) is administered 
intramuscularl y as a 2 -dose series spaced 21 day s apart at a dose of 30 μg each. Study  
C4591001 ([STUDY_ID_REMOVED]) is an ongoing Phase 1/2/3 trial in ~44,000 participants designed 
to generate safet y, tolerability ,immunogenicit y, and efficacy data from a novel RNA -based 
vaccine candidate.  The trial is being conducted in a heterogeneous study  population: eligible 
participants ≥12years of age, healthy  participants, including those participants with stable 
chronic m edical conditions, including HIV
-, HCV -, and HBV -positive participants.  The 
study  consists of 2 parts: Phase 1: to identify  the preferred vaccine candidate (BNT162b1 or 
BNT162b2) and dose level (10 µg, 20 µg, 30µg, or 100 µg [for BNT162b1]); Phase 2/3: a n 
expanded -cohort and efficacy part for the selected vaccine candidate (BNT162b2). 
BNT162b2 was selected from the Phase 1 part of this study  based on the overall safety , 
tolerability, and immunogenicity .Vaccine efficacy from Phase 2/3 for the primary  endpoint 
against confirmed COVID -19 occurring at least 7 day s after the second dose was 95% with 
8COVID -19 cases in the active vaccine group compared to 162 COVID-19 cases in the 
placebo group. Data from approximately  38,000 participants randomized 1:1 wit h a median 
of 2months of follow -up after the second dose of vaccine showed a favorable safet y profile 
at a dose of 30 μg in participants 16 y ears of age and older.
To optimize storage and distribution of this vaccine on a wide scale ,a lyophilized or alte rnate
formulation that will be stable at standard refrigerator or freezer temperatures isrequired.
Therefore, this study  will compare the safety andtolerability of lyophilized BNT162b2 
presented in SDV sto those of frozen -liquid BNT162b2 in MDV sand de termine whether the 
immune response is nonin ferior .Separatel y, the study  will also describe the safet y and 
immunogenicit y of frozen -liquid BNT162b2 with LNP size at the upper end of specification 
and RTU BNT162b2 (the immediate manufacturing precursor to the ly ophilate) .

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 10The primary  immunogenicity  analy sis demonstrated that the immune response elicited by  the 
lyophilized formulation did not meet the noninferiority  criteria compared to the frozen -liquid 
formulation of BNT162b2
. As a result, for the benefit of participants, all study  participants 
who received 2 doses of the ly ophilized formulation will be offered an additional vaccine 
dose, using the 
30-µg dose of frozen-liquid formulation of BTN162b2.
Objectives , Estimands, and Endpoints
Obje ctives Estimands Endpoints
Prim ary Immunogenicity
To demonstrate that the 
immune response induced by
lyophilized BNT162b2 in 
SDVs isnoninferior to the 
immune response induced by 
frozen -liquid BNT162b2 in 
MDVs in participants without 
evidence of SARS -CoV -2 
infection during the studyIn participants complying with the key 
protocol criteria (evaluable 
participants):
GMR of lyophilized formulation 
in SDVs to frozen -liquid 
formulation in MDVs 1 month 
after Dose 2Full-length S -binding IgG 
levels
Prim ary Safety
To evaluate the safety of 
BNT162b2 when administered 
on a 2 -dose schedule in healthy 
adults 18 through 55 years of 
ageIn participants receiving at least 
1dose of study intervention from each 
vaccine group, the percentage of 
participants reporting:
Local reactions for up to 7 days 
following each dose
Systemic events for up to 7 days 
following each dose
AEs and SAEs from Dose 1 
through 1month after Dose 2Local reactions (pain at the 
injection site, redness, and 
swelling)
Systemic events (fever, 
fatigue, headache, chills, 
vomiting, diarrhea, new or 
worsened muscle pain, and 
new or w orsened joint pain)
AEs
SAEs
Secondary Immunogenicity
To describe the immune 
responses induced by 
lyophilized BNT162b2 in
SDVs and frozen -liquid 
BNT162b2 in MDVsIn evaluable participants from each 
vaccine group:
GMCs at baseline (before Dose 1) 
and 1 month after Dose 2
GMFR from baseline (before 
Dose 1) to 1 month after Dose 2Full-length S -binding IgG 
levels
Exploratory
To describe the immune 
responses induced by frozen -
liquid BNT162b2 with LNP 
size at the upper end of 
specification and RTU 
BNT162b2 in participants 
without evidence of 
SARS -CoV- 2 infection during 
the stud yIn evaluable participants:
GMR offrozen -liquid BNT162b2 
with LNP size at the upper end of 
specification to frozen -liquid 
BNT162b2 in MDVs 1 month 
after Dose 2Full-length S -binding IgG 
levels and/or SARS -CoV- 2 
neutralizing titers

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 11Obje ctives Estimands Endpoints
To describe the immune 
responses induced by frozen -
liquid BNT162b2 with LNP 
size at the upper end of 
specification and RTU 
BNT162b2In evaluable participants from each 
vaccine group:
GMCs and/or GMTs at baseline 
(before Dose 1) and 1 month after 
Dose 2
GMFR from baseline (before 
Dose 1) to1 month after Dose 2Full-length S -binding IgG 
levels and/or SARS -CoV- 2 
neutralizing titers
To describe the safety profile of 
frozen -liquid BNT162b2 
formulation when given as a 
third dose to participants who 
originally received 2 doses of 
the lyophilized formulation of
BNT162 b2In participants who originally received 
2-dose series of the ly ophilized 
formulation of BNT162b2 :
Local reactions for up to 7 days 
following third dose
Systemic events for up to 7 days 
following third dose
AEs from Dose 3to 1 m onth after 
Dose3
SAEs from Dose 3to 1month 
after Dose3Local reactions (pain at the 
injection site, redness, and 
swelling)
Systemic events (fever, 
fatigue, headache, chills, 
vomiting, diarrhea, new or 
worsened muscle pain, and 
new or w orsened joint pain)
AEs
SAEs
To describe the immune 
response elicited by 
frozen -liquid BNT162b2
formulation when given as a 
third dose following a primary 
series of lyophilized BNT162b2In evaluable participants who 
originally received a 2-dose series of 
the lyophilized formulation o f 
BNT162b2
GMFR from prior to Dose 3 to 
1month after Dose 3
GMCs and/or GM Ts at baseline, 
at 1 month after Dose 2,prior to
Dose 3 ,and 1 month after Dose 3Full-length S -binding IgG 
levels and/or SARS -CoV- 2 
neutralizing titers

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 12Overall Design
This is a Phase 3, randomized, observer- blind study  to evaluate the safet y, tolerability , and 
immunogenicit y of multiple formulation sof BNT162b2, an RNA -based COVID -19 vaccine, 
administered on a 2 -dose schedule in healthy  adults 18 through 55 y ears of age . In Part 1,
participants will be randomized in a 1:1 ratio to 1 of the 2groups (l yophilized SDV or 
frozen- liquid MDV control for ly ophilized SDV ). Separatel y, in Part 2,participants will be 
randomized in a 1:1 ratio to 1 of the 2 groups ( frozen -liquid BNT162b2 with L NP size at the 
upper end of specification or RTU BNT162b2 ). The duration of the stud y for each 
participant will be approximately  2 months.  The study  will be conducted in the US with 
potential to expand to other countries.
Updates as part of protocol amendment 2:
All participants who originally  received 2 doses of the ly ophilized formulation of BNT162b2
will be offered 
the opportunity  to receive a third dose with the current frozen -liquid 
formulation of BNT162b2. Those participants who acc ept the offer of receiving a third dose 
will have 2additional visit
s. The study  duration will be extended for 1 additional month for 
those participants who accept the offer of receiving a third dose.
Number of Participants
Approximately  550participants will be randoml y assigned in a 1:1 ratio to either ly ophilized 
SDV or frozen -liquid MDV control for l yophilized SDV ;separatel y, approximately  
60participant swill be randomly  assigned in a 1:1 ratio to either frozen -liquid BNT162b2
with L NP size at the upper end of specification or RTU BNT162b2 , for a total of 
approximately  610 randomized participants .It is expected that approximately  488 evaluable 
participants will complete the study , based on a 20% nonevaluable rate.
Data Monitoring 
Committee or Other Independent Oversight Committee : Yes
This study  will use a DMC.  The DMC is independent of the study  team and includes 
external members.  The DMC charter describes the role of the DMC in more detail.
The DMC will be responsible for ongoi ng monitoring of the safety of participants in the 
study  according to the charter.  This may  include, but is not limited to:
Contemporaneous review of related AEs up to 1 month after completion of the 
vaccination schedule,
Contemporaneous review of all SAEs up to 1 month after completion of the 
vaccination schedule.
The recommendations made b y the DMC to alter the conduct of the stud y will be forwarded 
to the appropriate Pfizer personnel for final decision.  Pfizer will forward such decisions, 
which may  include summaries of aggregate analy ses of safety  data, to regulatory  authorities, 
as appropriate.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 13Statistical Methods
Theprimary  immunogenicity  objective will be evaluated b y a formal h ypothesis test for 
nonin feriority  ofthe full -length S -binding IgG level s induced b y lyophilized SDV compared 
to the corresponding frozen -liquid MDV BNT162b2 control .  GMR s will be provided along 
with associated 2 -
sided 95% CI s.Noninferiorit y will be declared if the lower bound of the 
2-sided 95% CIfor the GMR of ly ophilized BNT162b2 relative to frozen -liquid MDV 
BNT162b2 is greater than 0.67 ( using a 1.5-fold noninferiority criterion) .
With 220evaluable participants in each of the 2vaccine groups in Part 1, the study  has a 
power of 90.1% for declaring noninferiorit yof lyophilized BNT162b2 to frozen -liquid MDV 
BNT162b2 .Assuming a nonevaluable rate of 20%, the study  will randomize approximately  
275participants toeach group in Part 1 of the study  to achieve the required number of 
evaluable participant
s.
The secondary  immunogenicity  objective will be evaluated descriptivel y by GMCs, GMFRs, 
and the associated 95% CI s for the full -length S- binding IgG levels for each vaccine group.
The primary  safet y objective will be evaluated b y descriptive statistics i ncluding counts and 
percentages of participants and the associated Clopper-Pearson 95% CIs for local reactions, 
systemic events, and AEs/SAEs for each vaccine group.
1.2.Schema
Note: As part of protocol amendment 2, a ll participants who originally  receive d 2doses of
the 
lyophilized formulation of BNT162b2 will be offered the opportunit y to receive a third 
dose of the frozen -liquid formulation of BNT162b2.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 141.3. S chedule of Activ ities
The SoA table provides an overview of the protocol visits and procedures. Refer to the Study Assessments and Procedures section of 
the protocol for detailed information on each procedure and assessment required for compliance with the protocol.
The investigator may  sche dule visits (unplanned visits) in additio n to those listed in the SoA table , in order to conduct evaluations or 
assessments required to protect the well -being of the participant .
Visit Number 1 2 3
Visit Description Vaccination 1 Vaccination 2 1-Month Follow -up Visit
Visit Window Day 1a19 to 23 Days After Visit 1 28 to 35 Days After Visit 2
Obtain informed consent X
Assign participant number X
Obtain demography and medical history data X
Perform clinical assessmentbX
Measure height and w eight X
Measure temperature (body) X X
Perform urine pregnancy test (if appropriate) X X
Confirm use of contraceptives (if appropriate) X X X
Collect nonstudy vaccine information X X X
Collect prohibited medication use X X
Confirm eligibility X X
Revie w temporary  delay criteria X
Collect blood sample for immunogenicity assessment & for 
serological testing for prior COVID -19 infectionc~20 mL ~20 mL
Obtain nasal (midturbinate) swab for determination of current 
SARS -CoV- 2 statuscX X
Obtain randomization number and study intervention 
allocationX
Administer study intervention X X

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 15Visit Number 1 2 3
Visit Description Vaccination 1 Vaccination 2 1-Month Follow -up Visit
Visit Window Day 1a19 to 23 Days After Visit 1 28 to 35 Days After Visit 2
Assess acute reactions for at least 30 minutes after study 
intervention administrationX X
Explain/review participant communication methods 
(including for reactogenicity e -diary completion), assist the 
participant with downloading the app, or issue provisioned 
device, if requiredX X
Provide/ensure participant has a thermometer and measuring 
deviceX X
Revie w reactogenicity e -diary data (daily review is optimal 
during the active diary period)X X
Revie w ongoing reactogenicity e- diary symptoms with 
participant and obtain stop datesX X
Collect AEs and SAEs X X Xd
Collect e- diary or assist the participant to delete the 
applicationX
Abbreviations: = continuous/ongoing event; e -diary = electronic diary.
a.The visit may be conducted across 2 consecutive days; if so, all steps from assessing the inclusion and exclusion criteria on ward mu st be conducted on the 
same day.
b.Including, if indicated, a physical examination.
c.Administration of study intervention is not dependent on test result s.
d.Any AEs occurring up to 48 hours after blood draw and nasal swab collection must be recorded.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 161.3.1. Schedule of Activities for Those Participants Who Originally Received Lyophilized Formulation and Accept the Offer to 
Receive Current Frozen Formulation of BNT162b2
Visit Number 101 102
Visit Description Vaccination 3 1-Month Follow -up Visit
Visit Window At Least 90DaysAfter Vaccination 2 28 to 35 Days After Visit 101
Obtain informed consent X
Confirm participant originally received BOTH 
doses of lyophilized formulation of BNT162b2X
Measure prevaccination temperature (body) X
Perform urine pregnancy test (if appropriate) X
Confirm use of contraceptives (if appropriate) X X
Collect nonstudy vaccine information X X
Collect prohibited medication use X X
Revie w and consider eligibilityaX
Revie w temporary  delay criteria X
Collect blood sample for immunogenicity 
assessment~20 mL ~20 mL
Obtain nasal (midturbinate) swab for determination 
of current SARS -CoV-2 statusbX X
Obtain study intervention allocation using the IRT 
systemX
Administer study intervention X
Assess acute reactions for at least 30 minutes after 
study intervention administrationX
Provide thermometer and measuring device X
Remind participant of e -diary technologies X
Revie w reactogenicity e -diary data (daily review is 
optimal during the active diary period)X

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 17Visit Number 101 102
Visit Description Vaccination 3 1-Month Follow -up Visit
Visit Window At Least 90DaysAfter Vaccination 2 28 to 35 Days After Visit 101
Revie w ongoing reactogenicity e- diary symptoms 
and obtain stop dates X X
Collect AEs and SAEs as appropriatecX Xc
Collect e-diary or assist the participant to delete 
applicationX
Abbreviations: e -diary = electronic diary ;IRT = interactive response technology.
a.Confirm that the participant meetsall of the inclusion criteria and does not meet exclusion criteria 1, 3, 5, 6, 7, 10, 11, 12, 13, and 14.
b.Administration of study intervention is not dependent on test results
c.Any AEs occurring up to 48 hours after blood draw  and nasal swab collection must be recorded .

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 182.INTRODUCTION
BNT162b2 is an RNA -based COVID -19 vaccine that is currentl y in use via either emergency  
(temporary ) use or conditional marketing authoriz ations in approximately  70 countries for 
the prevention of COVID -19 in individuals ≥
16 ye ars of age .BNT162b2 received first 
temporary  authori zation for emergency  suppl y under regulation 174 in the UK on 
01December 2020 and is currentl y authori zed for emergency  use in 30 countries. 
BNT162 b2 received first regulatory  conditional marketing authori
zation approval in 
Switzerland on 19 December 2020 and is currently  conditionall y approved in 40 countries.
2.1.Study Rationale
The purpose of this stud y is to demonstrate that the immune response induc ed by  the 
refrigerator -stable ly ophilized formulation of BNT162b2 is noninferior to the frozen -liquid 
formulation of BNT162b2 in MDVs, and to describe the safety  and tolerability  of these 
different vaccine formulations in healthy  adults, there bysupporting refrigerated storage and
distribution at commercial scale. The study  will also descri be the safet y and immunogenicit y 
of frozen- liquid BNT162b2 with L NP size at the upper end of specification and RTU 
BNT162b2 .
Current clinical and EUA specifications for LNP  size for the frozen -liquid formulation are40
to 180 nm and 40 to 120 nm, respectivel y.Clinical experience ,however, is limited to LNP 
size in the range 59 to 74 nm , based on lots used in the clinic al studies already  conducted. 
Hence ,an exploratory study  arm is being 
included to better understand the impact of LNP 
size, using a lot with LNP size close to the upper specification boundary  (without any  
significant impact onother quality  attributes
).  The immediate manufacturing precursor of 
the ly ophilized formulation is the RTU . An exploratory  study  arm is included to describe the 
safet y and immunogenicity  of the RTU (ie ,precursor prior to the ly ophilization step ).
The primary  immuno genicity  analy sis demonstrated that the immune response elicited by the 
lyophilized formulation did not meet the noninferiority  criteria compared to the frozen -liquid 
formulation of BNT1 62b2 . As a result, for the benefit of the participants , all study  
participants who received 2 doses of the l yophilized formulation will be offered an additional
vaccine dose, using the 30-µg dose of the frozen- liquid formulation of BNT162b2.
2.2.Background
In December 2019, a pneumonia outbreak of unknown cause occurred in Wuhan, China.  
InJanuary  2020, it became clear that a novel coronaviru s (2019- nCoV) was the underl ying 
cause.  Later in January , the genetic sequence of the 2019 -nCoV became available to the 
WHO and the public (MN908947.3), and the virus was categorized in the Betacoronavirus
subfamily .  By  sequence anal ysis, the phy logeneti c tree revealed a closer relationship to 
SARS virus isolates than to another coronavirus infecting humans, the MERS virus.1,2
The outbreak was declared a Public Health Emergency  of International Concern on 
30January 2020.3  On 12 February  2020, the virus was officiall y named as severe acute 
respiratory  syndrome coronavirus 2 (SARS -CoV -2), and the WHO officially
 named the 
disease caused b y SARS -CoV -2 as coronavirus disease 2019 (COVID -19).3  SARS -CoV - 2 

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 19infections and the resulting disease, COVID -19, have spread globall y and on 11 March 2020, 
the WHO characterized the COVID -19 outbreak as a pandemic.4  On 08 January  2021, The 
Center for S ystems Science and Engineering at Johns Hopkins University  reported more than 
88million cases globall y, with over 1.
9million deaths from 1 91 countries.  The 
United States has reported more than 21.6 million cases and over 366,000 deaths.5
Since fall of 2020, the incidence of COVID -19 illnesses is increasing dramatically  in many  
northern hemisphere countries, including the United States, France, Germany , Italy, and the 
United Kingdom, raising the specter that as temperatures have fallen a nd the “respiratory  
virus season” has started, cases may  dramaticall y increase, potentiall y overwhelming 
healthcare infrastructures. This possibility  highlights the importance of developing a 
COVID -19 vaccine as quickly  as possible while ensuring that all safet y measures are met.
A proph ylactic, RNA -based SARS -CoV -2 vaccine provides one of the most flexible and 
fastest approaches available to immunize against the emerging virus.6,7In an attempt to 
prevent the spread of disease and to control the pandemic , numerous COVID -19 vaccine 
candidates are in development.
The development of an RNA -based vaccine encoding a viral antigen, which is then expressed 
by the vaccine recipient as a protein capable of eliciting protective immune responses, 
provides significan t advantages over more traditional vaccine approaches.  Unlike live 
attenuated vaccines, RNA vaccines do not carry the risks associated with infection and may  
be given to people who cannot be administered live virus (eg, pregnant women and 
immunocompromise d persons).  RNA -based vaccines are manufactured via a cell- free 
invitro transcription process, which allows an easy and rapid production and the prospect of 
producing high numbers of vaccination doses within a shorter time period than achieved with 
traditional vaccine approaches.  This capability  is pivotal to enable the most effective 
response in outbreak scenarios.6,7
BNT162b2 is a SARS -CoV -2–RNA - LNP vaccine based on a platform of modRNA with 
blunted innate immune sensor –activating capacit y and augmented expression encoding P2 S.
2.2.1.
Clinical Overview
Study  C4591001 ([STUDY_ID_REMOVED]) is an ongoing Phase 1 /2/3 trial in ~44,000 particip ants 
designed to generate safety , tolerabilit y, immunogenicity, and efficacy data from a novel 
RNA -based vaccine candidate.8  The trial is being conducted in a heterogeneous study  
population: eligible participants ≥12years of age, healthy  participants, including those 
participants with stable chronic medical conditions, including HIV
-, HCV -, and 
HBV -positive participants.  The study  consists of 2 parts: Phase 1: to identify  the preferred 
vaccine candidate (BNT162b1 or BNT162b2) and dose level (10 µg, 20 µg, 30 µg, or 100 µg 
[for BNT162b1]); Phase 2/3: an expanded- cohort and efficacy  part for the selected vaccine 
candidate (BNT162b2). BNT162b2 was selected from the Phase 1 part of this study  based 
on the overall safet y, tolerability , and immunogenicity .In a mid
-November 2020 anal ysis of 
36,621 participants randomized 1:1 to vaccine or placebo who were included in the 
per-protocol efficacy  analy sis population of participants without evidence of SARS -CoV -2 
infection prior to 7 day s after completion of the vaccination schedule , efficacy  in preventing 

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 20confirmed COVID -19 occurring at least 7 day s after the second dose of vaccine was 95.0%, 
with 8 COVI D-19 cases in the active vaccine group and 162 COVID -19 cases in the placebo 
group. Subgroup anal yses of the primary  efficacy  endpoint showed similar efficacy  point 
estimates across age groups, sexes, racial and ethnic groups, and participants with medical 
comorbidities associated with high risk of s evere COVID -19. Secondary  efficacy  anal yses 
suggested benefit of the vaccine in preventing severe COVID-19, in preventing COVID-19 
following the first dose, and in preventing COVID -19 in individuals with prior SARS -CoV -2 
infection, although available data for these outcomes did not allow for firm conclusions.9
Safety data from approximately  38,000 participants at least 16 y ears of age randomized 1:1 
to vaccine or placebo with a median of 2 months of follow-up after the second dose suggest a 
favorable safety  profile. Available safet y data from all participants enrolled through the 
14 November 2020 data cutoff (N=43,252, which includes late enrollment of additional 
adolescent and adult participants) w ereconsistent with the safet y profile for the 
approx imately  38,000 participants with a median follow -up of 2 months and also did not 
raise specific safet y concerns.9
The most common solicited adverse reactions were i njection site reactions (84.1%), fatigue 
(62.9%), headache (55.1%), muscle pain (38.3%), chills (31.9%), joint pain (23.6%), and 
fever (14.2%); severe adverse reactions occurred in 0.0% to 4.6% of participants, were more 
frequent after Dose 2 than after Do se 1, and were generall y less frequent in participants 
≥55years of age ( ≤2.8%) as compared to y ounger participants (≤4.6%). The frequency  of 
SAE s was low (<0.5%), without meaningful imbalances between stud y arms. Among 
nonserious unsolicited AEs, there was a numerical imbalance of 4 cases of Bell’s pals y in the 
active vaccine group com pared with no cases in the placebo group, though the 4cases in the 
active vaccine group do not represent a frequency above that expected in the general 
population. Otherw ise, there were no notable patterns or numerical imbalances between 
vaccine groups for specific categories of nonserious AEs (including other neurologic, 
neuroinflammatory , and thrombotic events) that would suggest a causal relationship to 
BNT162b2. With the exception of more frequent, generall y mild to moderate reactogenicit y 
in participants <55 years of age, the safet y profile of BNT162b2 was generally similar across 
age groups, sexe s, ethnic and racial groups, participants with or without medical 
comorbidities, and participants with or without evidence of prior SARS -CoV -2 infection at 
enrollment .9
In the C4591001 stud y, the Phase 1 population included health y participants 18 through 55 
and 65 through 85 years of age.  Enrollment in Phase 1 is complete and, although follow -up 
continues, the available safet y data from Phase 1 participants show that BNT162b2 
reactogenicity , AEs, and laboratory  results were consistent with those commonly  associated 
with vaccination.  The observed reactogenicity  was generall y mild or moderate (primarily 
pain at the injection site) and short-lived.  The local reactions tended to be more frequent 
after the second dose.  There was no redness or swelling reported b y participants in the 
65-through 85 -year age group who received BNT162b2.10
Regarding s ystemic events, 17% of the 18
-through 55 -year age group and 8% of those in the 
65-through 85 -year age group reported fever ( ≥38.0°C to 38.9°C) after the second dose of 

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 2130µg of BNT162b2.  Severe s ystemic events (fatigue, headache, chills, muscle pain, and 
joint pain) were reported in small numbers of y ounger recipients of this vaccine candidate, 
but no severe s ystemic events were reported in older recipients, and there were no Grade 4 
systemic events reported.10
No unexpected AEs or SAEs were reported.  Through 1 month after receipt of the second 
vaccination, AEs that were considered b y investigators to be related to the study  intervention 
were reported in 25% of participants 18 through 55 y ears of age who received 30 µg of 
BNT162b2; no AEs were reported b y the old er population who received the same dose.10
The available immunogenicity  data from Phase 1 participants show that BNT162b2 induced 
a robust IgG -binding response to S1 and a SARS- CoV -2–neutralizing response.  
Immunogenicit y substantially  increased following the second dose of vaccine.  BNT162b2 
induces a strong antigen -specific Th 1
–skewed CD4+ response and a strong antigen-specific 
CD8+ response.
Based on the safety ,tolerability , and immunogenicity  data generated from Phase 1, the 
vaccine candidate selected for the Phase 2/3 part of the study  was BNT162b2 at a dose 
of 30 µg.  This phase of the study is currentl y ongoing and is evaluating the efficacy  of the 
study  intervention
.
The Phase 2/3 portion of C4591001 was initiated in 18- through 85 -year-old adults but was 
amended in September 2020 to include participants ≥16 y ears of age.  It is intended that a 
minimum of 40% of participants will be in the >55 -year stratum. A further protocol 
amendment in October 2020 added a stratum of 2000 participants (1000 active vaccine) 
12through 15 years of age.  The first 360 participants in the Phase 2/3 part of the study  will 
be considered the Phase 2 segment but will also contrib ute to the efficacy  endpoint.
There are 2 primary  efficacy  endpoints in the Phase 2/3 part of the study.  The first is to 
evaluate the efficacy  of prophy lactic BNT162b2 against confirmed COVID- 19 in participants 
without evidence of infection before vaccina tion and the second is to evaluate the efficacy  of 
prophy lactic BNT162b2 against confirmed COVID -19 in participants regardless of evidence 
of infection before vaccination.  Cases of COVID -19 are defined b y the presence of specified 
symptoms plus anNAAT for SARS -CoV -2 at least 7 day s following the second dose of 
vaccine.  Effectiveness in 12 -to 15 -year-old participants will be inferred b y immune 
noninferiority  to that in 16-to 25 -year-old participants based on SARS -CoV -2–neutralizing 
GMT
s.
The primary  safety objective include sdefinition of the safet y profile of prophylactic 
BNT162b2 in the first 360 participants in the Phase 2 population, in all participants 
randomized in Phase 2/3, and in 12- to 15 -year-old participants.  Reactogenicity  will be 
assessed b y e-diary  in all participants in Phase 
1, in at least 6000 participants in Phase 2/3, 
and in all participants 12 through 15 years of age.
The scale of the BNT162b2 manufacturing has been increased to support future supply .  
Therefore, in the C4591001 Phase 2/3 phase of the study , BNT162b2 generated using the 

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 22manufacturing process supporting an increased supply  (“Process 2”) was administered to 
approximately  250 participants 16 through 55 years of age, per lot.
The currently  available safet y and immunogenicity data are presented in the BNT162 IB.11
2.3.Benefit/Risk Assessment
There is an ongoing global pandemic of COVID -19 and, based on the data available from the 
C4591001 study ,multiple temporary or em ergency  use authorizations and conditional 
marketing authorizations have been granted for BNT162b2. The available safet y and 
immunogenicit ydata from the ongoing Pfizer/BioNTech clinical trial combined with 
available nonclinical data with BNT162 vac cines, and data from nonclinical studies and 
clinical trials with the same or related RNA components, or antigens, support a favorable 
benefit/risk profile and support continued clinical development of BNT162b2.
In the C4591001 stud y, BNT 162b2 has been sho wn to elicit increased local and sy stemic 
adverse reactions as compared to those in the placebo arm, usuall y lasting a few days. The 
most common solicited adverse reactions were injection site reactions (84.1%), fatigue 
(62.9%), headache (55.1%), muscle p ain (38.3%), chills (31.9%), joint pain (23.6%), and 
fever (14.2%).9Adverse reactions characterized as reactogenicity  were generall y mild to 
moderate. The number of participant s reporting hy persensitivity -related AEs was 
numericall y higher in the active vacc ine group compared with the placebo group 
(137 [0.63%] vs 111 [0.51%]). Severe adverse reactions occurred in 0.0 % to 4.6% of 
participants, were more frequent after Dose 2 than after Dose 1, and were generall y less 
frequent in older adults (>55 years of age) (<2.8%) as compared to younger participants 
(≤4.6%). Among reported unsolicited AE s, lymphadenopathy  occurred much more 
frequentl y in the active vaccine group than the placebo group and is plausibly  related to 
vaccination. SAEs, while uncommon (<1.0%) , represented medical events that occur in the 
general population at similar frequency  as observed in the study .9
No specific safet y concerns were identified in subgroup anal yses by age, race, ethnicit y, 
medical comorbidities, or prior SARS -CoV -2 infection. Although participants 16 through
17years of age were enrolled in the P hase 3 trial, safet y data for this age group arelimited. 
However, available data are consistent with the safety  profile in the adult population, and it is 
biologicall y reasonable to extrapolate the greater safet y experience in adults, in particular 
younger adults, to the oldest pediatric age group of 16 through 17 years.  The potentia l risks 
are based on the observed safet y profile to date, which shows mostly  mild reactogenicity , low 
incidence of severe or serious events, and no clinically  concerning safet y observations. The 
preponderance of severe cases of COVID -19 in the placebo gro
up relative to the BNT162b2 
group (9 of 10) suggests no evidence of VAED.9Continued clinical investigation is justified 
given:
the urgent need to optimize storage and distribution of aCOVID -19 vaccine on a 
wide scale using a lyophilized formulation that will be stable at standard refrigerator 
temperatures
,

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 23the threat posed b y the increasing number of globally  distributed outbreaks of 
SARS -CoV -2 infection,
the potential of the BioNTech platform of RNA -based vaccines to rapidl y deliver 
high numbers of vaccine doses in a single production campaign.
More detailed information about the known and expected benefits and risks and reasonabl y 
expected AEs of BNT162b2 may  be found in the IB, which is the SRSD for this study .

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 242.3.1. Risk Assessment
Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Study Intervention: BNT162b2 RNA -Based COVID- 19 Vaccine
Local and systemic reactions to the vaccine may 
occur (injection site redness, injection site swelling, 
and injection site pain, fever, fatigue, headache, 
chills, muscle pain, and joint pain) following 
vaccination.These are common adverse reactions seen with 
other vaccines as well as the COVID -19 vaccine.
The most common events reported in Study 
C4591001 w ere mild to moderate pain at the 
injection site, fatigue ,and headache.The study employs the use of a reactogenicity 
e-diary to monitor local reactions and systemic 
even ts in real time.
All study participants will be observed for at 
least 30 minutes after vaccination.
Safety profile of a novel vaccine not yet fully 
characterized.
Adverse reactions (risks) identified from the 
postauthorization safety data include: 
Anaphylaxis, other hypersensitivity reactions 
(eg,rash, pruritus, urticaria, angioedema), pain in 
extremity (injected arm) .Data available from Study C4591001 show ed low  
incidence of severe or serious events, and no 
clinically concerning safety observatio ns across the 
safety population and within demographic 
subgroups based on age, sex, race/ethnicity, 
country, and baseline SARS -CoV -2 status.
Postauthorization safety data surveillance has 
confirmed the safety profile observed in C4591001 
and has resulted i n identification of some additional 
adverse reactions (risks) as noted in this table.Collection of AE and SAE reports from signing 
of the ICD t hrough 1month after the second 
dose of vaccine.
DMC throughout the study to review all safety 
data.
All participants will be observed for at least 
30minutes after vaccination.
Potential for COVID -19 enhancement. Disease enhancement has been seen following 
vaccination with RSV, feline coronavirus, and 
Dengue virus vaccines. No evidence of disease 
enhanceme nt has been seen in large- scale clinical 
study of BNT162b2 in humans or in 
postauthorization surveillance.Eligibility criteria will exclude any participants 
who have had a previous clinical 
(signs/symptoms only) or microbiological 
(signs/symptoms and posi tive SARS -CoV- 2 
NAAT result) diagnosis of COVID -19.This 
will minimize the low risk of potential disease 
enhancement and ensure that the immune 
response evaluated in the study is not impacted 
by serological changes due to previous 
COVID -19 disease.
Monito ring for cases of COVID- 19 developing 
during the study, which will be reported as 
AESIs.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 25Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Study Procedures
Participants will be required to attend healthcare 
facilities during the global SARS -CoV -2 pandemic.Without appropriate social distancing and PPE, 
there is a potential for increased exposure to 
SARS -CoV- 2.Pfizer w ill work with sites to ensure an 
appropriate COVID -19 prevention strategy.
The study will include m onitoring for cases of 
COVID -19 developing during the study, which 
will be reported as AES Is.
Venipuncture will be performed during the study. There is the risk of bleeding, bruising, hematoma 
formation, and infection at the venipuncture site.Only appropriately qualified personnel will obtain 
the blood draw .
Very  rare cases of anaphylaxis, myocarditis, and 
pericarditis have been reported after EUA in 
recipients of BNT162b2Anaphylaxis: The estimated rate is 5.0 per million 
doses administered.
Myocarditis and pericarditis: Very rare cases of 
myocarditis and per icarditis have been reported 
following vaccination with mRNA COVID -19 
vaccines. Typically, the secases have occurred 
more often in younger men and after the second 
dose of the vaccine and within 14 days after 
vaccination. These are generally mild cases and 
individuals tend to recover w ithin a short time 
following standard treatment and rest. Healthcare 
professionals should be alert to the signs and 
symptoms of myocarditis and pericarditis in vaccine 
recipients.Specific reference to these risks is made within the 
ICD, with instruction to contact a healthcare 
professional if a case is suspected.
For anaphylaxis, there is an on -site observation 
period of 30 -minute after vaccination.
Instructions for handling suspected cases o f 
myocarditis and pericarditis are found in 
Section 8.13.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 262.3.2. Benefit Assessment
Benefits to individual participants may  include:
Receipt of a n efficacious or potentially  efficacious COVID -19 vaccine during a 
global pandemic
Access to COVID -19 diagnostic testing
Contributing to research to help others in a time of global pandemic
2.3.3. Overall Benefit /Risk Conclus ion
Taking into account the measures taken to minimize risk sto participants participating in this 
study , the potential risks identified in association with BNT162b2 are justified by  the 
anticipated benefits that may  be afforded to healthy  participants.
3.OBJECTIVES, ESTIMAND S, AND ENDPOINTS
Objectives Estimands Endpoints
Prim ary Immunogenicity
To demonstrate that the immune 
response induced by lyophilized 
BNT162b2 in SDVs is 
noninferior to the immune 
response induced by frozen -
liquid BNT162b2 in MDVs in 
participants without evidence of 
SARS -CoV- 2 infection during 
the studyIn participants complying with the 
key protocol criteria (evaluable 
participants):
GMR of lyophilized 
formulation in SDVs relative 
to frozen -liquid formulation in 
MDVs 1 month after Dos e 2Full-length S -binding IgG 
levels
Prim ary Safety
To evaluate the safety of 
BNT162b2 when administered 
on a 2 -dose schedule in healthy 
adults 18 through 55 years of 
ageIn participants receiving at least 
1dose of study intervention from 
each vaccine group, the percentage 
of participants reporting:
Local reactions for up to 
7days following each dose
Systemic events for up to 
7days following each dose
AEs and SAEs from Dose 1 
through 1month after Dose 2Local reactions (pain at the 
injection site, redness, and 
swelling)
Systemic events (fever, 
fatigue, headache, chills, 
vomiting, diarrhea, new or 
worsened muscle pain, and 
new or w orsened joint pain)
AEs
SAEs
Secondary Immunogenicity
To describe the immune 
responses induced by lyophilized 
BNT162b2 in SDVs and 
frozen -liquid BNT162b2 in 
MDVsIn evaluable participants from each 
vaccine group:
GMCs at baseline (before 
Dose 1) and 1 month after 
Dose 2
GMFR from baseline (before 
Dose 1) to 1 month after 
Dose 2Full-length S -binding IgG 
levels

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 27Objectives Estimands Endpoints
Exploratory
To describe the immune 
response sinduced by frozen -
liquid BNT162b2 with LNP size 
at the upper end of specification 
and RTU BNT162b2 in 
participants without evidence of 
SARS -CoV- 2 infection during 
the studyIn evaluable participants:
GMR offrozen -liquid 
BNT162b2 w ith LNP size at 
the upper end of specification 
relative to frozen -liquid 
BNT162b2 in MDVs 1 month 
after Dose 2Full-length S -binding IgG 
levels and/or SARS -CoV- 2 
neutralizing titers 
To describe the immune 
responses induced by frozen -
liquid BNT162b2 with LNP size 
at the upper end of specification 
and RTU BNT162b2In evaluable participants from each 
vaccine group:
GMCs and/or GMTs at 
baseline (before Dose 1) and 
1month after Dose 2
GMF R from baseline (before 
Dose 1) to1 month after 
Dose 2Full-length S -binding IgG 
levels and/or SARS -CoV- 2 
neutralizing titers
To describe the safety profile of 
frozen -liquid BNT162b2 
formulation when given as a 
third dose to participants who 
originally received 2 doses of the 
lyophilized formulation of
BNT162b2In participants who originally 
received 2 dose series of the 
lyophilized formulation of 
BNT162b2 :
Local reactions for up to 7 days 
following third dose
Systemic events for up to 
7days following third dose
AEs from Dose 3to 1 m onth 
after D ose3
SAEs from Dose 3to 1month 
after Dose3Local reactions (pain at the 
injection site, redness, and 
swelling)
Systemic events (fever, fatigue, 
headache, chills, vomiting, 
diarrhea, new  or worsened 
muscle pain, and new or 
worsened joint pain)
AEs
SAEs
To describe the immune 
response elicited by frozen -
liquid BNT162b2 formulation 
when given as third
dose follow ing a primary series 
of lyophilized BNT162b2In evaluable participants who 
originally received 2 dose series of 
the lyophilized formulation of 
BNT162b2
GMFR from prior to Dose 3 to 
1 month after Dose 3
GMCs and/or GMTs at 
baseline, at 1 month after Dose 
2, prior to Dose 3 and 1 month 
after Dose 3 Full-length S -binding IgG 
levels and/or SARS -CoV- 2 
neutralizing titers
4.STUDY DESIGN
4.1.Overall Design
This is a Phase 3, randomized, observer- blind study  to evaluate the safet y, tolerability , and 
immunogenicit y of multiple formulation sof BNT162b2, an RNA -based COVID -19 vaccine, 
administered on a 2 -dose schedule in healthy  adults 18 through 55 y ears of age. The stud y 
will be conducted in the US with potential to expand to other countries .

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 28In Part 1, participants will receive either l yophilized BNT162b2 in SDVs or frozen- liquid 
BNT162b2 in MDVs.  In Part 2, participants will receive either frozen- liquid BNT162b2 
with L NP size at the upper end of specification or RTU BNT162b2. In Part 1,participants 
will be randomized in a 1:1 ratio to 1 of the 2 groups (lyophilized SDV or frozen- liquid 
MDV control for l yophilized SDV). Separately, in Part 2,participants will be randomized in 
a 1:1 ratio to 1 of the 2 groups (frozen -liquid BNT162b2 with L NP size at the upper end of 
specification or RTU BNT162b2). The duration of the study  for each participant will be 
approximately  2 months. Approximately  550 participants will be randoml y assigned to 
either ly ophilized SDV or frozen- liquid MDV control for lyophilized SDV; separately , 
approximately  60 participant s will be randomly  assigned to receive either frozen -liquid 
BNT162b2 with LNP size at the upper end of specification or RTU BNT162b2 , for a total of 
approximately  610 randomized participants. It is expected that approximately  488 evaluable 
participants will complete the study , based on a 20% nonevaluable rate.
Updates as part of 
protocol amendment 2: 
All participants who originally  received 2 doses of the ly ophilized formulation of BNT162b2 
will be offered the opportunity  to recei ve a third dose with the current frozen -liquid 
formulation of BNT162b2. Those participants who accept the offer of receiving third dose 
will have 2additional visits as described in Section 1.3.1 .The study  duration will be 
extended for 1 additional month for those participants who accept the offer of receiving a 
third dose.
4.2.Scientific Rationale for Study Design
This study  contains assessments that could be considered standard for a vaccine 
noninfe riority  study .  Blood samples taken for immunogenicit y will establish the level of 
immune response elicited by each formulation to provide the necessary  data to meet the 
primary  endpoint of the study .  Immunogenicit y will be assessed b y the full -length S -binding 
IgG assay .  To establish if a participant has as ymptomatic SARS -CoV -2 infection, nasal 
swabs for SARS -CoV -2 nucleic acid amplification testing (ie, NAAT) and blood samples to 
measure N-binding antibody  levels will be taken.  A positive result on either test will result 
in the immunogenicity  data from that participant being excluded from the evaluable portion 
of the study population.  All reactogenicity  and safety  assessments are standard for a study  of 
this nature.
This study  will not include a placebo, as the aim and design of this study  are not to 
demonstrate efficacy .
Human reproductive safety  data are not available for BNT162b2, but there is no suspicion of 
human teratogenicit y bas ed on the intended mechanism of action of the compound.  
Therefore, the use of a highly effective method of contraception is required (see Appendix 4 ).

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 294.3.Justification for Dose
Based on data from the Phase 1 component of clinica l trial C4591001 and available 
nonclinical data , the modRNA BNT162b2 vaccine candidate was selected at a dose of 30 µg 
for Phase 2/3 evaluation of safet y, immunogenicity, and efficacy. This is the dose that has 
shown to be effective and has been authorize d for temporary  or emergency use.
Update based on protocol amendment
2:
The primary  immunogenicity  analy sisdemonstrated that the immune response elicited by  the 
lyophilized formulation did not meet the nonin feriority  criteria compared to the frozen -liquid 
formulation. Therefore, all study  participants who received 2 doses of the ly ophilized 
formulation will be offered an additional 30 -ug dose of the frozen- liquid formulation.
4.4.End of Study Definition
A participant is considered to have completed the study  if he/she has completed all phases of 
the study , including the last visit.
The end of the stud y is defined as the date of the last visit of the last participant in the study.
5.STUDY POPULATION
This study  can fulfi ll its objectives only  if appropriate participant s are enrolled.  The 
following eligibility  criteria are designed to select participant s for whom participation in the 
study  is considered appropriate.  All relevant medical and nonmedical conditions should b e 
taken into consideration when deciding whether a particular participant is suitable for this 
protocol .
Prospective approval of protocol deviations to recruitment and enrollment criteria ,also 
known as protocol waivers or exemptions, is not permitted .
5.1.
Inclusion Criteria
Participants are eligible to be included in the study onl y if all of the following criteria appl y:
Age and Sex :
1.Male or female participants between the ages of 18 and 55 y ears, inclusive, at Visit 1 
(Day  1).
Refer to Section 10.4 for reproductive criteria for male ( Section 10.4.1 ) and female 
(Section 10.4.2) participants.
Type of Participant and Disease Characteristics:
2.Participants who are willing and able to compl y with all scheduled visits, treatment plan, 
laboratory  tests, lifest yle consid
erations, and other study  procedures.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 303.Health y participants who are determined b y medical history, ph ysical examination 
(ifrequired), and clinical judgment of the investigator to be eligible for inclusion in the 
study .
Note: Health y participants with preex isting stable disease, defined as disease not 
requiring significant change in therap y or hospitalization for worsening disease during 
the 6 weeks before enrollment, can be included.
Informed Consent:
4. Capable of giving personal signed informed consent as de scribed in Appendix 1 , which 
includes compliance with the requirements and restrictions listed in the I CD and in this 
protocol.
5.For Dose 3 : Participant swho received BOTH doses of thelyophilized formulation of 
BNT162b2 as part of the initial study .
5.2. Exclusion Criteria
Participants are excluded from the study  if any  of the following criteria apply :
Medical Conditions:
1.Other medical or psy chiatric condition including recent (within the past year) or active 
suicidal ideation/behavior or laboratory  abnormality  that may  increase the risk of study  
participation or, in the investigator’s judgment, make the participant inappropriate for the 
study .
2.Known infection with HIV, HCV, or HBV.
3.History  of severe adverse reaction associated with a vaccine and/or severe allergic 
reaction (eg, anaph ylaxis) to any  component of the study  intervention(s).
4.Previous clinical (based on COVID -19 s ymptoms/signs alone, if a SARS -CoV -2 NAAT 
result was not available) or microbiological (based on COVID -19 s ymptoms/signs and a 
positive SARS -CoV -2 NAAT result) diagnosis of COVID -19.
5. Immunocompromised individuals with known or suspected immunodeficiency , as 
determined b y history  and/or laboratory /physical examination.
6.Bleeding diathesis or condition associated with prolonged bleeding that would, in the 
opinion of the investigator, contraindicate intramuscular injection.
7.Women who are pregnant or breastfeeding.
Prior/Concomitant Therapy:
8.Previous vaccination with any coronavirus vaccine.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 319.Receipt of med ications intended to prevent COVID -19.
10.Individuals who receive treatment with radiotherapy  or immunosuppressive therap y, 
including cytotoxic agents or sy stemic corticosteroids (if sy stemic corticosteroids are 
administered for ≥14 days at a dose of ≥20 mg/d ay of prednisone or equivalent), eg, for 
cancer or an autoimmune disease, or planned receipt throughout the study .
Inhaled/nebulized, intra -articular, intrabursal, or topical (skin or ey es) corticosteroids are 
permitted.
11. Receipt of blood/plasma products or immunoglobulin, from 60 day s before study  
intervention administration or planned receipt throughout the stud y.
Prior/Concurrent Clinical Study Experience:
12.Participation in other studies involving study  intervention within 28 day s prior to study  
entry  and/or during study participation.
13.Previous participation in other studies involving study  intervention containing LNP s.
Other Exclusions:
14.Investigator site staff or Pfizer/BioNTech employees directly  involved in the conduct of 
the study , site staff otherwis e supervised b y the investigator, and their respective famil y 
members.
5.3.Lifestyle Considerations
5.3.1. Contraception
The investigator or his or her designee, in consultation with the participant, will confirm that 
the participant has selected an appropriate metho d of contraception for the individual 
participant and his or her partner(s) from the permitted list of contraception methods 
(seeSection 10.4.4) and will confirm that the participant has been instructed in its consistent 
and correct use.
At time points indicated in the SoA, the investigator or designee will i nform the participant 
of the need to use highl y effective contraception consistently  and correctly  and document the 
conversation and the participant’s affirmation in the participant’s chart (participants need to 
affirm their consistent and correct use of a t least 1 of the selected methods of contraception).  
In addition, the investigator or designee will instruct the participant to call immediately  if the 
selected contraception method is discontinued or if pregnancy  is known or suspected in the 
participant or partner.
5.4.Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study  but 
are not subsequently  randomly  assigned to study  intervention.  A minimal set of screen 
failure information is required to ensure tr ansparent reporting of screen failure participants to 
meet the CONSORT publishing requirements and to respond to queries from regulatory  

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 32authorities.  Minimal information includes demography , screen failure details, eligibility  
criteria, and an y SAEs.
Individuals who do not meet the criteria for participation in this study  (screen failure) may  be 
rescreened under a different participant number.
5.5. Criteria for Temporarily Delaying Enrollment/Randomization/Study Intervention 
Administration
The following conditions are temporary  or self -limiting and a participant may  be vaccinated 
once the condition(s) has/have resolved and no other exclusion criteria are met. Participants 
meeting these criteria at Vaccination 1 will be considered screen failures if enrollment h as 
closed once the condition(s) has/have resolved.
1.Current febrile illness (body  temperature ≥100.4°F [≥38.0°C]) or other acute illness 
within 48 hours before study  intervention administration.  This includes current 
symptoms that could represent a potenti al COVID -19 illness:
New or increased cough;
New or increased shortness of breath;
Chills;
New or increased muscle pain;
New loss of taste/smell;
Sore throat;
Diarrhea;
Vomiting.
2.Receipt of an y seasonal or pandemic influenza vaccine within 14 day s, or any  other 
nonstudy  vaccine within 28 days, before study  intervention administration.
3.
Anticipated receipt of any seasonal or pandemic influenza vaccine within 14 day s, or 
any other nonstudy  vaccine within 28 day s, after study  intervention administration.
4.Receipt of short -term (<14 day s) systemic corticosteroids.  Study  intervention 
administration should be delay ed until sy stemic corticosteroid use has been 
discontinued for at least 28 day s.  Inhaled/nebulized, intra -articular, intrabursal, or 
topical (skin or ey es) corticosteroids are permitted.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 336.STUDY INTERVENTION
Study  intervention is defined as any  investigational intervention(s), marketed product(s), 
placebo, medical device(s), or study  procedure(s) intended to be administered to a study  
participant acco rding to the study  protocol.
For the purposes of this protocol, study  intervention refers to BNT162b2, an RNA -based 
vaccine for immunization against COVID -19.  One of 3 versions of BNT162b2 (lyophilized ,
frozen- liquid , or RTU ) will be administered to each participant.  The stud y will evaluate a 
2-dose (separated b y 21 days) schedule in healthy adults 18 through 55 y ears of age.
6.1.Study Intervention(s) Administered
Intervention Name BNT162b2 
(BNT162 RNA
-LNP 
vaccine utilizing 
modRNA)BNT162b2 
(BNT162 RNA- LNP 
vaccine utilizing 
modRNA)BNT162b2 
(BNT162 RNA- LNP 
vaccine utilizing 
modRNA)
Arm  Nam e
(group of participants 
receiving a specific 
vaccine or no vaccine)Frozen -liquid MDV Lyophil ized SDV RTU SDV
Type Vaccine Vaccine Vaccine
Dose Form ulation modRNA modRNA modRNA
Dosage Level 30µg 30µg 30µg
Route of 
AdministrationIntramuscular injection Intramuscular injection Intramuscular injection
Use Experimental Experimental Experimental
IMP or NIMP IMP IMP IMP
Sourcing Provided centrally by the 
sponsorProvided centrally by the 
sponsorProvided centrally by the 
sponsor
Packaging and 
LabelingStudy intervention will be 
provided in a glass vial.  
Each vial will be labeled 
as required per country 
requirement.Study intervention will be 
provided in a glass vial.  
Each vial will be labeled 
as required per country 
requirement.Study intervention will be 
provided in a glass vial.  
Each vial will be labeled 
as required per country 
requirement.
6.1.1. Administration
Participants will receive 1 dose of study  intervention as randomized at each vaccination visit 
(Visits 1 and 2) separated by  21 day s in accordance with the study ’s SOA .Full details are 
described in the IP manual.
Participants who o riginally  received 2 doses of the lyophilized formulation of BNT162b2 
will be offered the opportunity to receive an additional dose of thefrozen -liquid formulation 
of BNT162b2 at least 90 day safter Dose 2.
Study  intervention should be administered intram uscularl y into the deltoid muscle, preferabl y 
of the nondominant arm, by  an unblinded administrator.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 34Standard vaccination practices must be observed and vaccine must not be injected into blood 
vessels.  Appropriate medication and other supportive measures for management of an acute 
hypersensitivity  reaction should be available in accordance with local guidelines for standard 
immunization practices.
Administration of study  interventions should be performed b y an appropriately  qualified, 
GCP -trained, and vacc ine-experienced member of the study  staff (eg, ph ysician, nurse, 
physician’s assistant, nurse practitioner, pharmacist, or medical assistant) as allowed by  
local, state, and institutional guidance.
Study  intervention administration details will be recorded on the CRF.
6.2.Preparation/Handling/Storage/Accountability
1. The investigator or designee must confirm appropriate temperature conditions have 
been maintained during transit for all study  interventions received and any  
discrepancies are reported and resolved b efore use of the study  intervention.
2.Only  participants enrolled in the study  may  receive study  intervention and only  
authorized site staff may  supply  or administer study  intervention.  All study 
interventions must be stored in a secure, environmentally  controlled, and monitored 
(manual or automated recording) area in accordance with the labeled storage 
conditions with access limited to the investigator and authorized site staff.  The 
temperature of all locations where study  intervention is stored at a clinical site must 
be monitored continuously .  At a minimum, daily  minimum and maximum 
temperatures for all site storage locations must be documented and available upon 
request.  Data for nonworking day s must indicate the minimum and maximum 
temperatures since previously  documented for all site storage locations upon return to 
business.
3.Any excursions from the study  intervention label storage conditions should be 
reported to Pfizer upon discovery  along with an y actions taken.  The site should 
activel y pursue options for returning the stud y intervention to the storage conditions 
described in the labeling, as soon as possible.  Once an excursion is identified, the 
study  intervention must be quarantined and not used until Pfizer provides permiss ion 
to use the study  intervention.  Specific details regarding the definition of an excursion 
and information the site should report for each excursion will be provided to the site 
in the I P manual.
4.Any storage conditions stated in the SRSD will be superseded b y the storage 
conditions stated on the label.
5.Study  interventions should be stored in their original containers.
6.See the IP manual for storage conditions of the study  intervention.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 357. The investigator, institution, or the head of the medical insti tution (where applicable) 
is responsible for stud y intervention accountability, reconciliation, and record 
maintenance (ie, receipt, reconciliation, and final disposition records), such as the 
IPAL or sponsor -approved equivalent.  All study  interventions w ill be accounted for 
using a study intervention accountabilit y form/record.
8.Further guidance and information for the final disposition of unused study  
interventions are provided in the I P manual.  All destruction must be adequately  
documented.  If destruction is authorized to take place at the investigator site, the 
investigator must ensure that the materials are destroy ed in compliance with 
applicable environmental regulations, institutional policy , and any  special instructions 
provided b y Pfizer.
Upon ide ntification of a product complaint, notify the sponsor within 1 business day  of 
discovery  as described in the I P manual.
6.2.1. Preparation and Dispensing
See the IP manual for instructions on how to prepare the stud y intervention for 
administration.  Study  inter vention should be prepared and dispensed b y an appropriatel y 
qualified and experienced member of the stud y staff (eg, ph ysician, nurse, phy sician’s 
assistant, nurse practitioner, pharmacy  assistant/technician, or pharmacist) as allowed by  
local, state, and institutional guidance.  A second staff member will verify  the preparation 
and dispensing.
Study  intervention will be prepared by  qualified unblinded site personnel according to the IP 
manual.  The stud y intervention will be administered in such a way as to ensure the 
participants remain blinded.
Requirements for site personnel to be blinded for the Dose 3 preparation arenot applica ble.
6.3.Measures to Minimize Bias: Randomization and Blinding
6.3.1. Allocation to Study Intervention
Allocation (randomization) of par ticipants to vaccine groups will proceed through the use of 
an IRT s ystem (I WR).  The site personnel (study  coordinator or specified designee) will be 
required to enter or select information including but not limited to the user’s I D and 
password, the prot ocol number, and the participant number.  The site personnel will then be 
provided with a vaccine assignment and randomization number.  The IRT system will 
provide a confirmation report containing the participant number, randomization number, and 
study  intervention allocation assigned.  The confirmation report must be stored in the site’s 
files.
The study -specific I RT reference manual and I P manual will provide the contact information 
and further details on the use of the IRT s ystem.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 366.3.2. B linding of Site Person nel
In this observer -blinded study , the study  staff receiving, storing, dispensing, preparing, and 
administering the stud y interventions will be unblinded.  All other study  and site personnel, 
including the investigator, investigator staff, and participant s, will be blinded to study  
intervention assignments.  I n particular, the individuals who evaluate participant safet y will 
be blinded.
The PIwill assign the responsibility  of the unblinded dispensers/administrators to persons 
who will not participate in t he evaluation of an y study  participant .  To ensure adequate 
coverage, at least 2 unblinded dispensers/administrators will be assigned per site.  Members 
of the study  site staff or clinic pharmacy  should fulfill these roles.  Contact between the 
unblinded dispensers and study  participants shoul d be kept to a minimum.  The investigator, 
study  coordinator, and any  site staff other than the unblinded dispensers/administrators must 
not be allowed to know the study  intervention assigned to an y study participant and must not 
be allowed to see the study intervention container contents.   Once the study  intervention has 
been prepared, there is no difference in the ph ysical appearance of the BNT162b2 
formulations. In the event of a Quality  Assurance audit, the auditor(s) will be allowed access 
to unblinde d study  intervention records at the site(s) to verify  that randomization/dispensing 
has been done accurately.
Update based on protocol amendment 2: 
After the complete data through 1 month after Dose 2 for Part 1 participant
swere available, 
the database for Part 1 was released and unblinded for the study  team to perform the 
statistical analy ses specified for P art 1. Additionally ,site staff and study  participants were 
also unblinded to participant s’vaccine allocation.
6.3.3. Blinding of the Sponsor
The majority of sponsor staff will be blinded to study  intervention allocation.  All laboratory  
testing personnel performing serology  assay s will remain blinded to study intervention 
assigned/received throughout the study .  The following sponsor staff, who will have n o part 
in the blinded conduct of the study , will be unblinded (further details will be provided in a 
data blinding plan):
Those study  team members who are involved in ensuring that protocol requirements 
for study  intervention preparation, handling, allocation, and administration are 
fulfilled at the site will be unblinded for the duration of the study  (eg, unblinded study  
manager, unblinded clinical research associate).
Unblinded clinician(s) who are not direct members of the study  team and will not 
partici pate in an y other study -related activities will review unblinded protocol 
deviations.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 37After the complete data through 1 month after Dose 2 for Part 1 participants were
available, the database for Part 1 was released and unblinded for the study  team to 
perform the statistical analy ses specified for Part 1.
6.3.4. Breaking the Blind
All study  participants will receive BNT162b2; blinding refers onl y to which vaccine 
formulation the participant will receive.  The IRT will be programmed with blind -breaking 
instructions.  I n case of an emergency , the investigator has the sole responsibility  for 
determining if unblinding of a participant’s study  intervention assignment is warranted.  
Participant safet y must alway s be the first consideration in making such a de termination.  If 
the investigator decides that unblinding is warranted, the investigator should make every  
effort to contact the sponsor prior to unblinding a participant’s vaccine assignment unless this 
could delay  further management of the participant.  If a participant’s vaccine assignment is 
unblinded, the sponsor must be notified within 24 hours after breaking the blind.  The date 
and reason that the blind was broken must be recorded in the source documentation and CRF.
The study -specific I RT reference manual and IP manual will provide the contact information 
and further details on the use of the IRT s ystem.
6.4. Study Intervention Compliance
When participants are dosed at the site, they  will receive study  intervention directly  from the 
investigator or desig nee, under medical supervision.  The date and time of each dose 
administered in the clinic will be recorded in the source documents and recorded in the CRF.  
The dose of stud y intervention and study participant identification will be confirmed at the 
time of dosing by a member of the stud y site staff other than the person administering the 
study  intervention.
6.5. Concomitant Therapy
The following concomitant medications and vaccinations will be recorded in the CRF:
All vaccinations received from 28 day s prior t o study  enrollment until the 1- month 
follow -up visit (Visit 3).
Additionally , for all participants receiving Dose 3, all vaccinations received from 
28days prior to Visit 101 (Dose 3) until the 1- month follow -up visit ( Visit 102).
Prohibited medications listed in Section 6.5.1 will be recorded, to include start and 
stop dates, name of the medication, dose, unit, route, and freq uency .
6.5.1. Prohibited During the Study
Receipt of the following vaccines and medications during the time periods listed below may  
exclude a participant from the per
-protocol anal ysis from that point onward and may require 
vaccinations to be discontinued in tha t participant; however, it is anticipated that the 
participant would not be withdrawn from the study  (see Section 7).  Medications sh ould not 
be withheld if required for a participant’s medical care.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 38Unless considered medically  necessary , no vaccines other than study  intervention 
should be administered within 28 day s before and 28 day s after each study  
vaccination.  One exception to thi s is that seasonal and pandemic influenza vaccine 
can be given at least 14 day s after, or at least 14 day s prior to, the administration of 
study  intervention.
Receipt of chronic s ystemic treatment with known immunosuppressant medications, 
or radiotherap y, within 60 day s before enrollment through conclusion of the study .
Receipt of s ystemic corticosteroids (≥ 20 mg/day  of prednisone or equivalent) for 
≥14days is prohibited from 28 day s prior to enrollment through Visit 3 orVisit 102 
for those partici pants receiving Dose 3 .
Receipt of blood/plasma products or immunoglobulins within 60 day s before 
enrollment through conclusion of the study .
Receipt of an y other (nonstudy ) coronavirus vaccine at an y time prior to or during 
study  participation is prohibited.
Receipt of proph ylactic medications intended to prevent symptoms associated with
COVID -19.  However, if a participant is taking a medication for another condition, 
even if it may  have such properties, it should not be withheld prior to study  
vaccination.
Prophy lactic antipy retics and other pain medication to prevent symptoms associated 
with study  intervention administration are not permitted.  However, if a participant is 
taking a medication for another condition, even if it may  have antipy retic or 
pain- relieving properties, it should not be withheld prior to study  vaccination.
6.5.2. Permitted During the Study
The use of antip yretics and other pain medication to treat symptoms associated with study  
intervention administration or ongoing conditions is permitted.
Medication other than that described as prohibited in Section 6.5.1 required for treatment of 
preexisting stable conditions is permitted.
Inhaled, topical, or localized injections of corticosteroids (eg, intra -articular or intrabursal 
administration) are permitted.
6.6.
Dose Modification
Not applicable for this study .
6.7.Intervention After the End of the Study
No intervention will be provided to study  participants at the end of the study .

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 397.DISCONTINUATION OF S TUDY INTERVENTION AN D PARTICIPANT 
DISCONTINUATION/WITH DRAWAL
7.1.Discontinuation of Study Intervention
In rare instances, it may  be necessary  for a participant to permanentl y discontin ue study  
intervention (definitive discontinuation).  Reasons for definitive discontinuation of study  
intervention include the following: AEs; participant request; investigator request; pregnancy; 
protocol deviation (including no longer meeting all the inclusion criteria, or meeting 1 or 
more exclusion criteria *).  I n general, unless the investigator considers it unsafe to administer 
the second dose, or the participant does not wish to receive it, it is preferred that the second 
dose be 
administered.
*A posi tive SARS -CoV -2 NAAT result without symptoms or a COVID -19 diagnosis 
(signs/s ymptoms only or signs/symptoms and a positive SARS -CoV -2 NAAT result) should 
not result in discontinuation of study  intervention.  If study  intervention (Dose 2) has been 
delay ed per Section 5.5, because of febrile or other acute illness (I tem 1 in the list in 
Section 5.5), and the investigator later diagnoses the signs and s ymptoms as COVID -19 (with 
or without a positive SARS -CoV -
2 NAAT result), the participant should not be discontinued 
from an y further doses of study intervention.
Note that discontinuation of study  intervention does not represent withdrawal from the study .  
Per the study  estimands, if study  intervention is de finitively  discontinued, the participant will 
remain in the study  to be evaluated for safet y and immunogenicit y.  See the SoA for data to 
be collected at the time of discontinuation of study intervention and follow -up for an y further
evaluations that need to be completed.
In the event of discontinuation of study  intervention, it must be documented on the 
appropriate CRF/in the medical records whether the participant is discontinuing further 
receipt of stud y intervention or also from s
tudy procedures, postvaccination study  follow -up, 
and/or future collection of additional information.
7.2.Participant Discontinuation/ Withdrawal F rom the Study
A participant may  withdraw from the study  at an y time at his/her own request.  Reasons for 
discontin uation from the study  include the following:
Refused further follow -up;
Lost to follow -up;
Death;
Study  terminated by  sponsor;
AEs;
Participant request; 

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 40Investigator request;
Protocol deviation.
If a participant does not return for a scheduled visit, ever y effort should be made to contact 
the participant.  All attempts to contact the participant and information received during 
contact attempts must be documented in the participant’s source document.  I n any  
circumstance, every  effort should be made to document participant outcome, if possible.
The investigator or his or her designee should capture the reason for withdrawal in the CRF 
for all participants.
If a participant withdraws from the study , he/she may  request destruction of any  remaining 
samples take n and not tested, and the investigator must document any  such requests in the 
site study  records and notify  the sponsor accordingly .
If the participant withdraws from the study  and also withdraws consent (see Section 7.2.1) 
for disclosure of future information, no further evaluations should be performed and no 
additional data should be collected.  The sponsor may  retain and continue to use any  data 
collected before su ch withdrawal of consent.
Lack of completion of all or an y of the withdrawal/earl y termination procedures will not be 
viewed as protocol deviations so long as the participant’s safet y was preserved.
7.2.1. Withdrawal of Consent
Participants who request to discontinue receipt of study  intervention will remain in the study  
and must continue to be followed for protocol -specified follow -
up procedures.  The onl y 
exception to this is when a participant specificall y withdraws consent for any further contact 
with h im or her or persons previously  authorized by  the participant to provide this 
information.  Participants should notify  the investigator in writing of the decision to 
withdraw consent from future follow- up, whenever possible.  The withdrawal of consent 
should be explained in detail in the medical records by  the investigator, as to whether the 
withdrawal is only  from further receipt of study  intervention or also from study  procedures 
and/or postvaccination study  follow -up, and entered on the appropriate CRF page.  In the 
event that vital status (whether the participant is alive or dead) is being measured, publicl y 
available information should be used to determine vital status only  as appropriately  directed 
in accordance with local law.
7.3.Lost to Fol low-up
A participant will be considered lost to follow- up if he or she repeatedl y fails to return for 
scheduled visits and is unable to be contacted b y the study  site.
The following actions must be taken if a participant fails to attend a required study  visit:
The site must attempt to contact the participant and reschedule the missed visit as 
soon as possible and counsel the participant on the importance of maintaining the 

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 41assigned visit schedule and ascertain whether or not the participant wishes to and/or 
should c ontinue in the study ;
Before a participant is deemed lost to follow-up, the investigator or designee must 
make every  effort to regain contact with the participant (where possible, 3 telephone 
calls and, if necessary, a certified letter to the participant’s last known mailing 
address or local equivalent methods).  These contact attempts should be documented 
in the participant’s medical record;
Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study.
8.STUDY ASSESSMENTS AND PRO CEDURES
The investigator (or an appropriate delegate at the investigator site) must obtain a signed and 
dated ICD before performing an y stud y-specific procedures.
The full date of birth will be collected to criticall y evaluate the immun e response and safet y 
profile b y age.
Study  procedures and their timing are summarized in the SoA .  Protocol waivers or 
exemptions are not allowed.
Safety  issues should be discussed with the sponsor immediately  upon occurrence or 
awareness to determine whether the participant should continue or discontinue study  
intervention.
Adherence to the study design requirements, including those specified in the SoA, is essential 
and required for stud y conduct.
All screeni ng evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility  criteria.  The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility  or record reasons for 
screening failure, as applicable.
Every  effort should be made to ensure that protocol -required tests and procedures are 
completed as described.  However, it is anticipated that from time to time there may  be 
circumstances outside the control of the inv estigator that may  make it unfeasible to perform 
the test.  I n these cases, the investigator must take all steps necessary  to ensure the safet y and 
well-being of the participant.  When a protocol- required test cannot be performed, the 
investigator will doc ument the reason for the missed test and an y corrective and preventive 
actions that he or she has taken to ensure that required processes are adhered to as soon as 
possible.  The study  team must be informed of these incidents in a timely  manner.
For sample s being collected and shipped, detailed collection, processing, storage, and 
shipment instructions and contact information will be provided to the investigator site prior 
to initiation of the study .

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 42The total blood sampling volume for individual participan ts in this study  is approximately  
40mL.  Additional blood samples may  be taken for safet y assessments at times specified b y 
Pfizer, provided the total volume taken during the study  does not exceed 550 mL  during an y 
period of 60 consecutive day s.
Per protocol amendment 2, those participants who accept the offer to receive Dose 3 will 
have an additional approximately  20-mL blood sample collected for immunogenicity  
assessments at each visit .
8.1.Efficacy and/or 
Immunogenicity Assessments
Serum samples will be obtained for immunogenicity  testing at the visits specified in the SoA.  
The test to be performed will be the SARS -CoV -2 full -length S -binding IgG -level assay .  
Note that all immunogenicity  analy ses will be base d upon samples anal yzed at the central 
laboratory .
Nasal (midturbinate) swabs at the visits specified in the SoA will be obtained as one of the 
determinations for participants to be included in the evaluable immunogenicity  anal ysis. 
These samples will be tested at the central laboratory  using an RT -PCR test (Cepheid, an 
NAAT; FDA approved under EUA) to detect SARS -CoV -2.  Another determination for 
participants to be included in the evaluable immunogenicity  anal ysis is the N -binding 
antibody  assay .  Blood samples will be taken at visits specified in the SoA and anal yzed at 
the central laboratory .  A positive result on either test will result in the immunogenicity  data 
from that participant being excluded from the evaluable portion of the study  population.  
However, administration of study  intervention is not dependent on these test results, which 
will be available only after the study  has ended.
8.1.1. Biological Samples
Blood and nasal swab samples will be used only  forscientific research.  Each sample will be 
labeled with a code so that the laboratory  personnel testing the samples will not know the 
participant’s identity .  Samples that remain after performing assay s outlined in the protocol 
may be stored by  Pfizer.  Unless a time limitation is required b y local regulations or ethical 
requirements, the samples will be stored for up to 15 y ears after the end of the study  and then 
destroy ed.  If allowed by  the I CD, stored samples may  be used for additional testing to bette r 
understand the immune responses to the vaccine(s) under stud y in this protocol, to inform the 
development of other products, and/or for vaccine- related assay  work supporting vaccine 
programs.  No testing of the participant’s genetic material will be perf ormed.
The participant may  request that his or her samples, if still identifiable, be destroy ed at any  
time; however, an y data alread y collected from those samples will still be used for this 
research.  The biological samples may  be shared with other resea rchers as long as 
confidentiality  is maintained and no testing of the participant’s genetic material is performed.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 438.2.Safety Assessments
Planned time points for all safety  assessments are provided in the SoA.  Unscheduled clinical 
laboratory  measurements may  be obtained at any  time during the stud y to assess any 
perceived safety  issues.
A clinical assessment, including medical history , will be performed on all participants at their 
first visit to establish a b aseline.  Significant medical history  and observations from any  
physical examination, if performed, will be documented in the CRF.
AEs and SAEs are collected, recorded, and reported as defined in Section 8.3.
Acute reactions within the first 30 minutes after administration of the study  intervention will 
be assessed and documented in the AE CRF.
The safet y parameters also include reactogenicit y e
-diary  reports of local reactions, sy stemic 
events (including fever), and use of antip yretic medication that occur in the 7 day s after 
administration of the study  intervention.  These prospectivel y self -collected occurrences of 
local reactions and s ystemic events are graded as described in Section 8.2.2 .
8.2.1. Clinical Safety Laboratory Assessments
Clinical safety  laboratory assessments will not be collected in this study .
See Section 10.5, Appendix 5, for suggested actions and follow-up assessments in the event 
of potential DILI.
8.2.2. Electronic Diary
Participants will be required to complete a reactogenicity  e-diary  through an application 
installed on a provisioned device or on the participant’ s own personal device.  All 
participants will be asked to monitor and record local reactions, sy stemic events, and 
antipy retic medication usage for 7 days from the day  of administration of the study  
intervention.  The reactogenicity  e-diary  allows recordin
g of these assessments only  within a 
fixed time window, thus providing the accurate representation of the participant’s experience 
at that time.  Data on local reactions and systemic events reported in the reactogenicit y 
e-diary  will be transferred electro nically  to a third- party vendor, where they will be available 
for review b y investigators and the Pfizer clinicians at all times via an internet -based portal.
At intervals agreed to b y the vendor and Pfizer, these data will be transferred electronicall y 
into Pfizer's database for anal ysis and reporting.  These data do not need to be reported by  the 
investigator in the CRF as AEs.
Investigators (or designee) will be required to review the reactogenicity  e-diary  data online at 
frequent intervals as part of th e ongoing safet y review.
The investigator or designee must obtain stop dates from the participant for any  ongoing 
local reactions, sy stemic events, or use of antipyretic medication on the last day  that the 

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 44reactogenicity  e-diary  was completed.  The stop da tes should be documented in the source 
documents and the information entered in the CRF.
8.2.2.1. Grading Scales
The grading scales used in this study  to assess local reactions and systemic events as 
described below are derived from the FDA CBER guidelines on toxic ity grading scales for 
healthy  adult volunteers enrolled in preventive vaccine clinical trials.12
8.2.2.2. Local Reactions
During the reactogenicit y e-diary  reporting period, participants will be asked to assess 
redness, swelling, and pain at the injection site and to record the s ymptoms in the 
reactogenicity  e-diary .  If a local reaction persists bey ond the end of the reactogenicity  
e-diary  period following vaccination, the participant will be requested to report that 
information.  The investigator will enter this a dditional information in the CRF.
Redness and swelling will be measured and recorded in measuring device units 
(range: 1to21) and then categorized during anal ysis as absent, mild, moderate, or severe 
based on the grading scale in Table 1.  Measuring device units can be converted to 
centimeters according to the following formula: 1 measuring device unit = 0.5 cm.  Pain at 
the injection site will be asse ssed by the participant as absent, mild, moderate, or severe 
according to the grading scale in Table 1.
If a Grade 3 local reaction is reported in the reactogenicity  e-diary , a telephone contact 
should occur to ascertain further details and determine whether a site visit is clinically  
indicated.  Onl y an investigator or medicall y qualified person is able to classify  a 
participant’s local reaction as Gra de4.  If a participant experiences a confirmed Grade 4 local 
reaction, the investigator must immediately  notify  the sponsor and, if it is determined to be 
related to the administration of the study  intervention, further vaccinations will be 
discontinued i n that participant.
Table 1. Local Reaction Grading Scale
Mild 
(Grade 1)Moderate 
(Grade 2)Severe 
(Grade 3)Potentially Life 
Threatening 
(Grade 4)
Pain at the 
injection siteDoes not interfere 
with activityInterferes with activity Prevents daily 
activity Emergency room visit 
or hospitalization for 
severe pain
Redness >2.0 cm to 5.0 cm 
(5 to 10 measuring 
device units)>5.0 cm to 10.0 cm 
(11to 20 measuring 
device units)>10cm 
(≥21measuring 
device units)Necrosis or exfoliative 
dermatitis
Swelling >2.0 cm to 5.0 cm 
(5 to 10 measuring 
device units)>5.0 cm to 10.0 cm 
(11to 20 measuring 
device units)>10cm 
(≥21measuring 
device units)Necrosis

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 458.2.2.3. Systemic Events
During the reactogenicit y e-diary  reporting period, participants will be asked to assess 
vomiting, diarrhea, headache, fatigue, chills, new or worsened muscle pain, and new or 
worsened joint pain and to record the s ymptoms in the reactogenicit y e-diary .  The symptoms 
will be assessed b y the participant as absent, mild, moderate, or severe according to the 
grading scale in Table 2.
If a Grade 3 s ystemic event is reported in the reactogenicity  e-diary , a telephone contact 
should occur to ascertain further details and determine whether a site visit is clinically  
indicated.  Onl y an investigator or medicall y qualified person is able to classify  a 
participant ’s systemic event as Grade
4.  If a participant experiences a confirmed Grade 4 
systemic event, the investigator must immediately notify  the sponsor and, if it is determined 
to be related to the administration of the study  intervention, further vaccination s will be 
discontinued in that participant.
Table 2. Systemic Event Grading Scale
Mild 
(Grade 1)Moderate 
(Grade 2)Severe 
(Grade 3)Potentially Life 
Threatening 
(Grade 4)
Vom iting 1-2 times in 
24hours>2 times in 
24hoursRequires IV 
hydrationEmergency room visit 
or hospitalization for 
hypotensive shock
Diarrhea 2 to 3 loose stools 
in 24 hours4 to 5 loose stools 
in 24 hours6 or more loose stools 
in 24 hoursEmergency room visit 
or hospitalization for 
severe diarrhea
Headache Does not interfere 
with activitySome interference 
with activityPrevents daily routine 
activityEmergency room visit 
or hospitalization for 
severe headache
Fatigue/tiredness Does not interfere 
with activitySome interference 
with activityPrevents daily routine 
activityEmergency room visit 
or hospitalization for 
severe fatigue
Chills Does not interfere 
with activitySome interference 
with activityPrevents daily routine 
activityEmergency room visit 
or hospitalization for 
severe chills
New or w orsened 
muscle painDoes not interfere 
with activitySome interference 
with activityPrevents daily routine 
activityEmergency room visit 
or hospitalization for 
severe ne w or worsened 
muscle pain
New  or w orsened 
joint painDoes not interfere 
with activitySome interference 
with activityPrevents daily routine 
activityEmergency room visit 
or hospitalization for 
severe ne w or worsened 
joint pain
Abbreviation: IV = intravenous.
During the 7 days following each vaccination, potential COVID -19 symptoms that overlap 
with solicited sy stemic events (ie, fever, chills, new or increased muscle pain, diarrhea, 
vomiting) should be assessed by  the investigator.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 46If, in the investigator’s opinion, the sy mptoms are considered more likely  to be vaccine 
reactogenicity , but a participant is required to demonstrate that he or she is
SARS -CoV -2–negative, a local SARS -CoV -2 test may  be performed: if positive, the 
symptoms should be recorded as an AE rather than as sy stemic events in the reactogenicity  
e
-diary .
8.2.2.4. Fever
In order to record information on fever, a thermometer will be given to participants with 
instructions on how to measure oral temperature at home.  Temperature will be collected in 
the reactogenicit y e-diary in the evening dail y during the reactogenicit y e-diary  reporting 
period.  It will also be collected at an y time during the reactogenicit y e-diary  data collection 
periods when fever is suspected.  Fever is defined as an oral temperature ≥38.0°C (100.4°F).  
The highest temperature for each day  will be recorded in the reactogenicit y e-diary .  
Temperature will be measured and recorded to 1 decimal place.  Temperatures recorded in 
degrees Fahrenheit will be programmatically  converted to degrees Celsius and then 
categorized according to the scale shown i n Table 3during anal ysis.
If a fever of 
≥39.0°C (102.1°F) is reported in the reactogenicity  e-diary , a telephone contact 
should occur to ascertain furt her details and determine whether a site visit is clinically  
indicated.  Onl y an investigator or medicall y qualified person is able to confirm a 
participant’s fever as >40.0°C (>104.0°F).  If a participant experiences a confirmed fever 
>40.0°C (>104.0°F), the investigator must immediately  notify  the sponsor and, if it is 
determined to be related to the administration of the study  intervention, further vaccinations 
will be discontinued in that participant.
Table 3. Scale for Fever
≥38.0 -38.4°C (100.4 -101.1°F)
>38.4 -38.9°C (101.2 -102.0°F)
>38.9 -40.0°C (102.1 -104.0°F)
>40.0°C (>104.0°F)
8.2.2.5. Antipyretic Medication
The use of antip yretic medication to treat s ymptoms associated with study  intervention 
administration will be recorded in the reactogenicity  e-diary  daily during the reporting period 
(Day  1 through Day 7).
8.2.3. Pregnancy Testing
Pregnancy  tests may  be urine or serum tests, but must have a sensitivity  of at least 
25mIU/mL.  Pregnancy  tests will be performed in WOCBP at the times l isted in the SoA , 
immediately  before the administration of each vaccine dose.  A negative pregnancy  test result 
will be required prior to the participant’s receiving the study  intervention.  Pregnancy  tests 

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 47may also be repeated if re quested b y IRBs/ECs or if required b y local regulations.  I n the 
case of a positive confirmed pregnancy , the participant will be withdrawn from 
administration of study  intervention but may  remain in the study .
8.3. Adverse Events and Serious Adverse Events
The definitions of an AE and an SAE can be found in Appendix 3 .
AEs will be reported b y the participant (or, when appropriate, b y a caregiver, surrogate, or 
the participant's legall y authorized representative).
The inves tigator and an y qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible to pursue 
and obtain adequate information both to determine the outcome and to assess wheth er the 
event meets the criteria for classification as an SAE or caused the participant to discontinue 
the study  intervention (see Section 7.1).
Each participant will be questioned about the occurrence of AEs in a nonleading manner.
In addition, the investigator may  be requested by  Pfizer Safet y to obtain specific follow -
up 
information in an expedited fashion.
8.3.1. Time Period and Frequency for C ollecting AE and SAE Information
The time period for actively  eliciting and collecting AEs and SAEs (“active collection 
period”) for each participant begins from the time the participant provides informed consent, 
which is obtained before the participant’s participation in the study  (ie, before undergoing 
any study -related procedure and/or receiving study  intervention), through and including 
Visit 3 (1- month follow -up).  In addition, an y AEs occurring up to 48 hours after the blood 
draw and nasal swab collection at Visit 3 reported by  the participant must be recorded in the 
CRF .SAEs will be collected from the time the 
participant provides informed consent 
through approximately  1month after the last dose of study  intervention (Visit 3).
For all participants receiving Dose 3 , AEs and SAEs will be collected from the time the 
participant provides informed consent for the receipt of Dose 3 at Visit 101 through 
Visit 102.
Follow -up by  the investigator continues throughout and after
the active collection period and 
until the AE or SAE or its sequelae resolve or stabilize at a level acceptable to the 
investigator and Pfizer concurs with that assessment.
For participants who are screen failures, the active collection period ends when s creen failure 
status is determined.
If the participant withdraws from the study and also withdraws consent for the collection of 
future information, the active collection period ends when consent is withdrawn.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 48If a participant definitively  discontinues or temporarily  discontinues study  intervention 
because of an AE or SAE, the AE or SAE must be recorded on the CRF and the SAE 
reported using the Vaccine SAE Reporting Form.
Investigators are not obligated to activel y seek AEs or SAEs after the participant has
concluded stud y participation .  However, if the investigator learns of an y SAE, including a 
death, at an y time after a participant has completed the study, and he/she considers the event 
to be reasonably  related to the study  intervention, the investigator must promptly  report the 
SAE to Pfizer using the Vaccine SAE Reporting Form.
8.3.1.1. Reporting SAEs to Pfizer Safety
All SAEs occurring in a participant during the active collection period as described in 
Section 8.3.1 are reported to Pfizer Safety  on the Vaccine SAE Reporting Form immediatel y 
upon awareness and under no circumstance should this exceed 24 hours, as indicated in 
Appendix 3.  The investigator will submit any  updated SAE data to the sponsor within 
24 hours of it being available.
8.3.1.2. Recording Nonserious AEs and SAEs on the CRF
All nonserious AEs and SAEs occurring in a participant d uring the active collection period, 
which begins after obtaining informed consent as described in Section 8.3.1 ,will be recorded 
on the AE section of the CRF.
The investigator is to record on the CRF all directly  observed and all spontaneously  reported 
AEs and SAEs reported by  the participant.
8.3.2. Method of Detecting AEs and SAEs
The method of recording, evaluating, and assessing causality of AEs and SAEs and the 
procedures for completing and transmitting SAE reports are provided in Section 10.3.
Care will be taken not to introduce bias when detecting AEs and/or SAEs.  Open -ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about AE 
occurr ences.
8.3.3. Follow -
up of AEs and SAEs
After the initial AE/SAE report, the investigator is required to proactivel y follow each 
participant at subsequent visits/contacts.  For each event, the investigator must pursue and 
obtain adequate information until resolut ion, stabilization, the event is otherwise explained, 
or the participant is lost to follow- up (as defined in Section 7.3).
In general, follow -
up information will include a description of the event in sufficient detail to 
allow for a complete medical assessment of the case and independent determination of 
possible causality .  An y information relevant to the event, such as concomit ant medications 
and illnesses, must be provided.  In the case of a participant death, a summary of available 
autopsy  findings must be submitted as soon as possible to Pfizer Safety .

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 49Further information on follow -up procedures is given in Appendix 3 .
8.3.4. Regulatory Reporting Requirements for SAEs
Prompt notification by  the investigator to the sponsor of an SAE is essential so that legal 
obligations and ethical responsibilities towards the safet y of participants and the saf ety of a 
study  intervention under clinical investigation are met.
The sponsor has a legal responsibility  to notify  both the local regulatory  authority  and other 
regulatory  agencies about the safet y of a stud y intervention under clinical investigation.  The
sponsor will comply  with country -specific regulatory  requirements relating to safet y 
reporting to the regulatory  authorit y, IRBs/ECs, and investigators.
Investigator safety  reports must be prepared for SUSARs according to local regulatory  
requirements and sponsor policy  and forwarded to investigators as necessary .
An investigator who receives SUSARs or other specific safet y information (eg, summary or 
listing of SAEs) from the sponsor will review and then file it along with the SRSD(s) for the 
study  and wi ll notify  the IRB/EC, if appropriate according to local requirements.
8.3.5. Exposure During Pregnancy or Breastfeeding, and Occupational Exposure
Exposure to the study  interventio nunder stud y during pregnancy  or breastfeeding and 
occupational exposure are repor table to Pfizer Safety  within 24 hours of investigator 
awareness.
8.3.5.1. Exposure During Pregnancy
An EDP occurs if: 
A female participant is found to be pregnant while receiving or after discontinuing 
study  intervention.
A male participant who is receiving or has discontinued study  intervention exposes a 
female partner prior to or around the time of conception.
A female is found to be pregnant while being exposed or having been exposed to 
study  intervention due to environmental exposure.  Below are examples of 
environmental exposure during pregnancy :
A female family  member or healthcare provider reports that she is pregnant after 
having been exposed to the study  intervention by  inhalation or skin contact.
A male famil y member or healthcare provider who has been exposed to the study  
intervention by  inhalation or skin contact then exposes his female partner prior to 
or around the time of conception.
The investigator must report EDP to Pfizer Safety within 24 hours of the investigator’s 
awareness, irrespective of wh ether an SAE has occurred.  The initial information submitted 

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 50should include the anticipated date of delivery  (see below for information related to 
termination of pregnancy).
If EDP occurs in a participant or a participant’s partner, the investigator must report 
this information to Pfizer Safety  on the Vaccine SAE Reporting Form and an EDP 
Supplemental Form, regardless of whether an SAE has occurred.  Details of the 
pregnancy  will be collected after the start of study  intervention and until 1 month 
after th e last dose of study  intervention.
If EDP occurs in the setting of environmental exposure, the investigator must report 
information to Pfizer Safety  using the Vaccine SAE Reporting Form and EDP 
Supplemental Form.  Since the exposure information does not pe rtain to the 
participant enrolled in the study , the information is not recorded on a CRF; however, 
a cop y of the completed Vaccine SAE Reporting Form is maintained in the I SF.
Follow -up is conducted to obtain general information on the pregnancy  and its outcome for 
all EDP reports with an unknown outcome.  The investigator will follow the pregnancy  until 
completion (or until pregnancy  termination) and notify  Pfizer Safet y of the outcome as a 
follow -up to the initial EDP Supplemental Form.  In the case of a live birth, the structural 
integrit y of the neonate can be assessed at the time of birth.  In the event of a termination, the 
reason(s) for termination should be specified and, if clinically  possible, the structural 
integrit y of the terminated fetus shou ld be assessed by  gross visual inspection (unless 
preprocedure test findings are conclusive for a congenital anomal y and the findings are 
reported).
Abnormal pregnancy  outcomes are considered SAEs.  If the outcome of the pregnancy  meets 
the criteria for an SAE (ie, ectopic pregnancy , spontaneous abortion, intrauterine fetal 
demise, neonatal death, or congenital anomal y), the investigator should follow the procedures 
for reporting SAEs.  Additional information about pregnancy  outcomes that are reported to 
Pfizer Safety  as SAEs follows:
Spontaneous abortion including miscarriage and missed abortion;
Neonatal deaths that occur within 1 month of birth should be reported, without regard 
to causality , as SAEs.  In addition, infant deaths after 1 month should be re ported as 
SAEs when the investigator assesses the infant death as related or possibly  related to 
exposure to the study  intervention.
Additional information regarding the EDP may  be requested by  the sponsor.  Further 
follow -up of birth outcomes will be hand led on a case -by-case basis (eg, follow -up on 
preterm infants to identify developmental delay s).  In the case of paternal exposure, the 
investigator will provide the participant with the Pregnant Partner Release of Information 
Form to deliver to his partne r.  The investigator must document in the source documents that 
the participant was given the Pregnant Partner Release of Information Form to provide to his 
partner.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 518.3.5.2. Exposure During Breastfeeding
An exposure during breastfeeding occurs if: 
A female partic ipant is found to be breastfeeding while receiving or after 
discontinuing study  intervention.
A female is found to be breastfeeding while being exposed or having been exposed to 
study  intervention (ie, environmental exposure).  An example of environmental 
exposure during breastfeeding is a female family  member or healthcare provider who 
reports that she is breastfeeding after having been exposed to the study  intervention 
by inhalation or skin contact.
The investigator must report exposure during breastfeedi ng to Pfizer Safety  within 24 hours 
of the investigator’s awareness, irrespective of whether an SAE has occurred.  The 
information must be reported using the Vaccine SAE Reporting Form.  When exposure 
during breastfeeding occurs in the setting of environme ntal exposure, the exposure 
information does not pertain to the participant enrolled in the study , so the information is not 
recorded on a CRF.  However, a cop y of the completed Vaccine SAE Reporting Form is 
maintained in the I SF.
An exposure during breast
feeding report is not created when a Pfizer drug specificall y 
approved for use in breastfeeding women (eg, vitamins) is administered in accord with 
authorized use.  However, if the infant experiences an SAE associated with such a drug, the 
SAE is reported together with the exposure during breastfeeding.
8.3.5.3. Occupational Exposure
An occupational exposure occurs when a person receives unplanned direct contact with the 
study  intervention, which may  or may  not lead to the occurrence of an AE.  Such persons 
may include healthcare providers, famil y members, and other roles that are involved in the 
trial participant’s care.
The investigator must report occupational exposure to Pfizer Safet y within 24 hours of the 
investigator’s awareness, regardless of whether there is an associated SAE.  The information 
must be reported using the Vaccine SAE Reporting Form.  Since the information does not 
pertain to a participant enrolled in the study, the information is not recorded on a CRF; 
however, a cop y of the completed Vaccine S AE Reporting Form is maintained in the I SF.
8.3.6. Cardiovascular and Death Events
Not applicable.
8.3.7. Disease -Related Events and/or Disease -Related Outcomes Not Qualifying as AEs 
or SAEs
Not applicable.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 528.3.8. Adverse Events of Special Interest
This section provides information on AESI s that may  be detected during the study :
Confirmed COVID -19 diagnosis (clinical signs/s ymptoms and positive SARS -CoV -2 
NAAT test)
A confirmed diagnosis of my ocarditis or pericarditis. See Section 8.13 for additional 
procedures for monitoring of potential my ocarditis or pericarditis.
All AESI s must be reported as an AE or SAE following the procedures described in 
Section 8.3.1 through Section 8.3.4.  An AESI  is to be recorded as an AE or SAE on the 
CRF.  I
n addition, an AESI  that is also an SAE must be reported using the Vaccine SAE 
Reporting Form.
8.3.8.1. Lack of Efficacy
Lack of efficacy  is reportable to Pfizer Safet y only if ass ociated with an SAE.
8.3.9. Medical Device Deficiencies
Not applicable.
8.3.10. Medication Errors
Medication errors may  result from the administration or consumption of the study  
intervention by the wrong participant , or at the wrong time, or at the wrong dosage strength.
Exposures to the study  intervention under stud y may occur in clinical trial settings, such as 
medication errors.
Safety Event Recorded on the CRF Reported on the Vaccine SAE Reporting Form  
to Pfizer Safety Within 24 Hours of Awareness
Medication errors All (regardless of whether 
associated with an AE)Only if associated with an SAE
Medication errors include:
Medication errors involving participant exposure to the study  intervention;
Potential medication errors or uses outside of what is foreseen in th e protocol that do 
or do not involve the study  participant;
The administration of expired study  intervention;
The administration of an incorrect study  intervention;
The administration of an incorrect dosage;

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 53The administration of study  intervention that ha s undergone temperature excursion 
from the specified storage range, unless it is determined by  the sponsor that the study  
intervention under question is acceptable for use.
Such medication errors occurring to a stud y participant are to be captured on the m edication 
error page of the CRF, which is a specific version of the AE page.
In the event of a medication dosing error, the sponsor should be notified within 24 hours .
Whether or not the medication error is accompanied by  an AE, as determined by  the 
investigator, the medication error is recorded on the medication error page of the CRF and, if 
applicable, an y associated AE(s), serious and nonserious, are recorded on theAE page of the 
CRF.
Medication errors should be reported to Pfizer Safety within 24 hours on a Vaccine SAE 
Report ingForm only when associated with an SAE .
8.4.Treatment of Overdose
For this study , any  dose of study  intervention greater than 1 dose of study  intervention within 
a 24-hour time period will be considered an overdose.
Pfizer does not recommend specific treatment for an overdose.
In the event of an overdose, the investigator should:
1.Contact the medical monitor within 24 hours.
2.Closely  monitor the participant for an y AEs/SAEs.
3.Document the quantit y of the excess dose as well as the duration of the overdose in 
the CRF.
4.Overdose is reportable to Safety  only when associated with an SAE .
Decisions regarding dose interruptions or modifications will be mad e by the investigator in 
consultation with the medical monitor based on the clinical evaluation of the participant.
8.5.Pharmacokinetics
Pharmacokinetic parameters are not evaluated in this study .
8.6.Pharmacodynamics
Pharmacod ynamic parameters are not evaluated i n this study .
8.7.Genetics
Genetics (specified anal yses) are not evaluated in this study .

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 548.8.Biomarkers
Biomarkers are not evaluated in this study .
8.9.Immunogenicity Assessments
Immunogenicit y assessments are described in Section 8.1.
8.10. Health Economics
Health e conomics/ medical resource utilization and health e conomics parameters are not 
evaluated in this study .
8.11. Study Procedures
8.11.1.
Visit 1 – Vaccination 1 (Day 1)
Before enrollment and before an y stud y
-related procedures are performed, voluntary , written, 
study -specific informed consent will be obtained from the participant.  Each signature on the 
ICD must be personall y dated b y the signatory. The investigator or his or her designee will 
also sign the ICD.  A copy  of the signed and dated I CD must be given to the participant.  The 
source data must reflect that the informed consent was obtained before participation in the 
study .
It is anticipated that the procedures below will be conducted in a stepwise manner. The visit 
may be conducted across 2 consecutive day s; if so, all steps from assessing the inclusion and 
exclusion criteria onward must be conducted on the same day .
Assign a single partici pant number using the IRT sy stem.
Obtain the participant’s demograph y (including date of birth, sex, race, and ethnicity).  
The full date of birth will be collected to criticall y evaluate the immune response and 
safet y profile b y age.
Obtain an y medical hi story  of clinical significance.
Perform a clinical assessment.  If the clinical assessment indicates that a phy sical 
examination is necessary to comprehensivel y evaluate the participant, perform a 
physical examination and record any  findings in the source documents and, if 
clinically  significant, record on the medical history  CRF.
Measure the participant’s height and weight.
Ensure and document that all of the inclusion criteria and none of the exclusion 
criteria are met.
Measure the participant’s body  temperature.
Perform urine pregnancy test on WOCBP as described in Section 8.2.3.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 55Discuss contraceptive use as described in Section 5.3.1 .
Record n onstudy  vaccinations as described in Section 6.5.
Collect a blood sample of approximately  20 mL for immunogenicit y testing and to 
test for prior COVID -19.  Please refer to the ISF for further instructions.
Obtain a nasal (midturbinate) sw ab (collected by  site staff) for determination of 
current SARS -CoV -2 status.  Please refer to the ISF for further instructions.
A blinded site staff member obtains the randomization number using the IRT sy stem.  
An unblinded site staff member then enters t he participant number (SSI D) and 
randomization number to assign the stud y intervention allocation number.
Unblinded site staff member(s) will dispense/administer 1 dose of study  intervention 
into the deltoid muscle of the 
(preferably )nondominant arm.  Ple ase refer to the I P 
manual for further instruction on this process.
Blinded site staff must observe the participant for at least 30 minutes after study  
intervention administration for an y acute reactions.  Record an y acute reactions 
(including time of onse t) in the participant’s source documents and on the AE page of 
the CRF, and on an SAE form as applicable.
Explain the e -diary  technologies available for this study  (Section 8.2.2), and assist the 
participant in downloading the stud y application onto the participant’s own device or 
issue a provisioned device if required.
Provide instructions on reactogenicity  e
-diary  completion and ask the participant 
to complete the reactogenicity  e-diary  from Day 1 through Day  7, with Day 1 
being the day  of vaccination.
Ask the participant to contact the site staff or investigator immediatel y if the 
participant experiences any  of the following from Day 1 through Day  7 after 
vaccination (where Day  1 is the day  of vaccination) to determine if an unscheduled 
reactogenicity  visit is required: 
Fever ≥39.0°C (≥102.1°F).
Redness or swelling at the injection site measuring greater than 10 cm 
(>20 measuring device units).
Severe pain at the injection site.
Any severe s ystemic event.
Issue a measuring device to measure local reactions at the injection site and a 
thermometer for recording daily temperatures and provide instructions on their use.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 56Record AEs/SAEs as described in Section 8.3.
Ask the participant to contact the site staff or investigator if a medicall y attended 
event (eg, docto r’s visit, emergency  room visit) or hospitalization occurs.
Ask the participant to contact the site staff or investigator if he/she develops 
symptoms of a COVID -19 infection, as defined by the CDC,13including:
New or increased cough;
New or increased short ness of breath;
Chills;
New or increased muscle pain;
New loss of taste/smell;
Sore throat;
Diarrhea;
Vomiting.
Schedule an appointment for the participant to return for the next study  visit.
Remind the participant to bring the reactogenicit y e-diary  to th e next visit.
Complete the source documents.
The investigator or an authorized designee completes the CRFs and an unblinded 
dispenser/administrator updates the study  intervention accountability records.
The investigator or appropriately  qualified designee reviews the reactogenicity  e-diary  data 
online following vaccination to evaluate participant compliance and as part of the ongoing 
safet y review.  Dail y review is optimal during the active diary  period.
8.11.2. Visit 2 – Vaccination 2 (19 to 23 Days After Visit 1)
Record AEs/SAEs as described in Section 8.3.
Review the participant’s reactogenicity  e-diary  data.  Collect stop dates of any  
react ogenicity  e-diary  events ongoing on the last day  that the reactogenicity  e-diary  
was completed and record stop dates in the CRF if required.
Perform urine pregnancy test on WOCBP as described in 
Section 8.2.3.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 57Discuss contraceptive use as described in Section 5.3.1 .
Record nonstud y vaccinations as described in Section 6.5.
Record details of any  of the prohibited medications specified in Section 6.5.1
received b y the participant if required for his or her clinical care.
Ensure and document that all of the inclusion criteria and none of the exclusion 
criteria are met.  If these eligibility  criteria are notmet, the participant may  not 
receive further st udy intervention but will remain in the study  to be evaluated for 
safet y, immunogenicity, and efficacy (see Section 7).
A positive SA RS-CoV -2 NAAT result without symptoms or a COVID -
19 
diagnosis (signs/sy mptoms only  or signs/sy mptoms and a positive SARS -CoV -2 
NAAT result) should not result in discontinuation of study  intervention.
If study  intervention (Dose 2) has been delay ed per the criteria for temporary  
delay , because of febrile or other acute illness (I tem 1, criteria for temporary  
delay ), and the investigator later diagnoses the signs and sy mptoms as COVID -19 
(with or without a positive SARS -CoV -2 NAAT result), the participant sho uld not 
be discontinued from an y further doses of study intervention.
Measure the participant’s body  temperature.
Ensure that the participant meets none of the temporary  delay  criteria as described in
Section 5.5.
Unblinded site staff member(s) will dispense/administer 1 dose of study  intervention 
into the deltoid muscle of the ( preferably )nondominant arm.  Please refer to the 
IPmanual for further instruction on this process.
Blinded site staff must observe the participant for at least 30 minutes after study  
intervention administration for an y acute reactions.  Record an y acute reactions 
(including time of onset) in the participan t’s source documents and on the AE page of 
the CRF, and on an SAE form as applicable.
Ensure the participant has a measuring device to measure local reactions at the 
injection site and a thermometer for recording daily temperatures.
Ensure the participant remains comfortable with the chosen e -diary  platform, confirm 
instructions on e -diary  completion, and ask the participant to complete the 
reactogenicity  e-diary  from Day 1 through Day  7, with Day 1 being the day of 
vaccination.
Ask the participant to conta ct the site staff or investigator immediatel y if the 
participant experiences any  of the following from Day 1 through Day  7 after 

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 58vaccination (where Day  1 is the day  of vaccination) to determine if an unscheduled 
reactogenicity  visit is required: 
Fever ≥39.0°C ( ≥102.1°F).
Redness or swelling at the injection site measuring greater than 10 cm 
(>20 measuring device units).
Severe pain at the injection site.
Any severe s ystemic event.
Ask the participant to contact the site staff or investigator if a medicall yattended 
event (eg, doctor’s visit, emergency  room visit) or hospitalization occurs.
Ask the participant to contact the site staff or investigator if he/she develops 
symptoms of a COVID -19 infection, as defined by the CDC ,13including:
New or increased cough; 
New or increased shortness of breath;
Chills;
New or increased muscle pain;
New loss of taste/smell;
Sore throat;
Diarrhea;
Vomiting.
Schedule an appointment for the participant to return for the next study  visit.
Remind the participant to bring the reactogenicit y e-diary  to the next visit.
Complete the source documents.
The investigator or an authorized designee completes the CRFs and an unblinded 
dispenser/administrator updates the study  intervention accountability records.
The investigator or appropriately  qualified designee reviews the reactogenicity  e-diary  data 
online following vaccination to evaluate participant compliance and as par t of the ongoing 
safet y review.  Dail y review is optimal during the active diary  period.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 598.11.3. Visit 3 – 1- Month Follow -up (28 to 35 Days After Visit 2)
Record AEs/SAEs as described in Section 8.3.
Review the participant’s reactogenicity  e-diary  data.  Collect stop dates of any  
reactogenicity  e-diary  events ongoing on the last day  that the reactogenicity  e-diary  
was completed and rec ord stop dates in the CRF if required.
Record nonstud y vaccinations as described in Section 6.5.
Record details of an y of the prohibi ted medications specified in Section 6.5.1
received b y the participant if required for his or her clinical care.
Discuss 
contraceptive use as described in Section 5.3.1.
Collect a blood sample of approximately  20 mL for immunogenicit y testing and to 
testfor prior COVID -
19.
Obtain a nasal (midturbinate) swab (collected b y site staff) for determination of 
current SARS -CoV -2 status.
Collect the participant’s reactogenicity  e-diary  or assist the participant to remove the 
study  application from his or her own personal device.
Complete the source documents.
The investigator or an authorized designee completes the CRFs.
8.11.4. Unscheduled Visits for a Grade 3 or Suspected Grade 4 Reaction
If a Grade 3 local reaction ( Section 8.2.2.2), s ystemic event ( Section 8.2.2.3 ), or fever 
(Section 8.2.2.4) is reported in the reactogenicit y e-diary , a telephone contact should occur to 
ascertain further details and determine whether a site visit is clinically  indicated. If a 
suspected Grade 4 local reaction ( Section 8.2.2.2), sy stemi c event ( Section 8.2.2.3), or fever 
(Section 8.2.2.4) is reported in the reactogenicit y e-diary , a telephone contact or site visit 
should occur to confirm whether the event meets the criteria for Grade 4.
A site visit must be scheduled as soon as possible to assess t he participant unless any  of the 
following is true:
The participant is unable to attend the unscheduled visit.
The local reaction/s ystemic event is no longer present at the time of the telephone 
contact.
The participant recorded an incorrect value in the r eactogenicity  e-diary  (confirmation 
of a reactogenicity  e
-diary  data entry  error).

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (15 May 2020)
Page 60The PI  or authorized designee determined it was not needed.
This telephone contact will be recorded in the participant’s source documentation and the 
CRF.
If the participant is unable to attend the unscheduled visit, or the PI  or authorized designee 
determined it was not needed, an y ongoing local reactions/sy stemic events must be assessed 
at the next study  visit.
During the unscheduled visit, the reactions should be assessed by the investigator or a 
medically  qualified member of the study  staff such as a study  physician or a study  nurse, as 
applicable to the investigator’s local practice, who will:
Measure bod y temperature (°F/°C).
Measure minimum and maximum diameters of redn ess (if present).
Measure minimum and maximum diameters of swelling (if present).
Assess injection site pain (if present) in accordance with the grades provided in 
Section 8.2.2.2 .
Assess sy stemic events (if present) in accordance with the grades provided in 
Section 8.2.2.3.
Assess for other findings associated with the reaction and record on the AE page of 
the CRF, if appropriate.
The investigator or an authorized designee will complete the unscheduled visit assessment 
page of the CRF.
8.12. Study Proc edures for Part icipants 
Who Accept the O ffer to Receive Dose 3
8.12.1. Visit 101 – Vaccination 3 ( At Least 90 D ays A fter Visit 2)
Before Vaccination 3 and before an y stud y-related procedures are performed, voluntary , 
written, study -specific informed consent will be obtained from the participant. Each 
signature on the ICD must be personall y dated b y the signatory .The investigator or his or 
her designe e will also sign the I CD. A cop y of the signed and dated ICD must be given to 
the participant. The source data must reflect that the informed consent was obtained before 
participation in the study .
It is anticipated that the procedures below will be conducted in a stepwise manner.
Confirm that the participant originally received lyophilized formulation of BNT162b2
at Vaccinations 1 and 2. Secondary  confirmation by  another site staff is required.
Measure the participant’s body  temperature.
PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 61Perform urine p regnancy test on WOCBP as described in Section 8.2.3.
Discuss contraceptive use as described in Section 5.3.1.
Record nonstud y vaccinations as described in Section 6.5.
Record details of an y of the prohibited medications specified in Section 6.5.1
received b y participant if required for his or her clinical care.
Review and consider inclusion criteria 2, 3, 4, and 5and exclusion criteria .
Confirm that the participant meet s
all of the inclusion criteria and does not meet 
exclusion criteria 1, 3, 5, 6, 7, 10, 11, 12, 13, and 14.
Ensure that the participant does not meet any  of the temporary  delay  criteria as 
described in 
Section 5.5.
Collect a blood sample of approximately  20 m L for immunogenicit y testing. Please 
refer to the ISF for further instructions.
Obtain a nasal (midturbinate) swab (collected b y site staff) for determination of 
current SARS -CoV -2 status. Please refer to the ISF for further instructions.
Obtain 
the participant’s vaccine allocation vialusing the IRT s ystem.
Dispense/administer 1 dose of study  intervention into the deltoid muscle of the 
(preferabl y)nondominant arm. Please refer to the I P manual for further instruction 
on thi s process.
Observe the participant for at least 30 minutes after study  intervention administration 
for an y acute reactions. Record an y acute reactions (including time of onset) in the 
participant’s source documents and on the AE page of the CRF, and on an SAE form 
as applicable.
Issue a measuring device to measure local reactions at the injection site and a 
thermometer for recording daily temperatures and provide instructions on their use.
Remind the participant of the e -diary  technologies available for th is study  
(Section 8.2.2 ), and assist the participant in downloading the stud y application onto 
the participant’s own device or issue a provisioned device if required.
Provide instructions on reactogenicity  e-diary completion and ask the participant 
to complete the reactogenicity  e-diary  from Day 1 through Day  7, with Day 1 
being the day  of vaccination.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 62Ask the participant to contact the site staff or investigator immediatel y if the 
participant experiences any  of the following from Day 1 through Day 7 after 
vaccination (where Day  1 is the day  of vaccination) to determine if an unscheduled 
reactogenicity  visit is required: 
Fever ≥39.0°C (≥102.1°F).
Redness or swelling at the injection site measuring greater than 10 cm 
(>20 measuring device units).
Severe pain at the injection site.
Any severe s ystemic event.
Record AEs/SAEs as described in Section 8.3.
Ask the participant to contact the site staff or investigator if a medicall y attended 
event (eg, doctor’s visit, emergency  room visit) or hospitalization occurs.
Ask the participant to contact the site staff or investigator if he/she develops 
symptoms of a COVID -19 infection, as defined by the CDC,13including:
New or increased cough; 
New or increased shortness of breath;
Chills;
New or increased muscle pain;
New loss of taste/smell;
Sore throat;
Diarrhea;
Vomiting.
Schedule an appointment for the participant to return for the next study  visit.
Remind the participant to bring the reactogenicit y e-diary  to the next visit.
Complete the source documents.
The investigator or an authorized designee completes the CRFs and an unblinded 
dispenser/administrator updates the study  intervention accountability  records.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 63The investigator or appropriately  qualified designee reviews the reactogenicity  e-diary  data 
online following vaccination to evaluate participant compliance and as part of the ongoing 
safet y review. Daily review is optimal during the active diary  period.
8.12.2. Visit 102 – 1- Month Follow -up (28 to 35 Days After Visit 101)
Record AEs/SAEs as described in Section 8.3.
Review the participant’s reactogenicity  e-diary  data. Collect stop dates of any  
reactogenicity  e-diary  events ongoing on the last day  that the reactogenicity  e-diary  
was completed and record stop dates in the CRF if required.
Record nonstud y vaccinations as described in Section 6.5.
Record details of an y of the prohibited medications specified in Section 6.5.1
received b y the participant if required for his or her clinical care.
Discuss contraceptive us e as described in Section 
5.3.1.
Collect a blood sample of approximately  20 mL for immunogenicit y testing.
Obtain a nasal (midturbinate) swab (collected b y site staff) for determination of 
current SARS -CoV -2 status. Please 
refer to the ISF for further instructions.
Collect the participant’s reactogenicity  e-diary  or assist the participant to remove the 
study  application from his or her own personal device.
Complete the source documents.
The investigator or an authorized desi gnee completes the CRFs.
8.13. Additional Procedures for Monitoring of Potential Myocarditis or Pericarditis
Any study  participant who reports acute chest pain, shortness of breath, palpitations, or any  
other sy mptom(s) that might be indicative of m yocarditis or pericarditis within 4 weeks of a 
study  vaccination should be specifically  evaluated, preferabl y by a cardiologist, for possible 
myocarditis or pericarditis.
In addition to a clinical evaluation, the following should be performed:
ECG
Troponin level
If my ocarditis or pericarditis are suspected based upon the initial evaluation, the following 
should also be performed:
Cardiac echocardiogram, and/or

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 64Cardiac magnetic resonance study
Details of the s ymptoms reported, and results of the investigations performed, will be 
recorded in the CRF.
9.STATISTICAL CONSIDERATIONS
Methodology for summary  and statistical anal yses of the data collected in this study  is 
described here and further detailed in a SAP, which will be maintained by  the sponsor.  The 
SAP may  modify  what is outlined in the protocol where appropriate; however, any  major 
modifications of the primary  endpoint definitions or their anal yses will also be ref lected in a 
protocol amendment.
9.1.Estimands and Statistical Hypotheses
9.1.1. Estimands
The estimands corresponding to each primary  and secondary  objective are described in the 
table in Section 3.
The estimands to evaluat e the immunogenicity  objectives are based on the evaluable 
immunogenicit y population ( Section 9.3).  These estimands estimate the vaccine effect in the 
hypothetical settings where participants follow the study  schedules and protocol requirements 
as directed.  The estimands address the objective of estimating the maximum potential 
difference between 2 groups, since the impact of noncompliance is likely  to diminish the 
observed difference between the 2 groups.  Missing antibody  results will not be imputed.  
Immunogenicit y results that are below the LLOQ will be set to 0.5 × LLOQ in the anal ysis; 
this may be adjusted once additional data on the assay  characteristics become available.
In the primary  safet y objective evaluations, missing reactogenicity e -diary data will not be 
imputed.  Missing AE start dates will be imputed according to Pfizer safet y rules.
  No other 
missing information will be imputed in the safet y analysis.
9.1.2. Statistical Hypothesis
The primary  immunogenicity  objective is to assess the noninferiorit y of the immune response 
induced b y lyophilized SDV compared to frozen -liquid MDV BNT162b2. The null 
hypothesis (H 0) is
H0: ln(μ 1) –ln(μ 2) ≤ ln( 0.67)vs H 1: ln(μ 1) –ln(μ 2) > ln(0.67 )
where ln( 0.67) corresponds to a 1.5- fold margin for noninferiorit y and 
ln(μ 1) is the natural log of the geometric mean of full -length S -binding IgG levels 
measured 1 month after Dose 2 from participants receiving l yophilized SDV 
BNT162b2 ;

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 65ln(μ 2) is the natural log of the geometric mean of full- length S -binding IgG levels 
measured 1 month after Dose 2 from participants receiving frozen -liquid MDV 
BNT162b2 control for l yophilized SDV 
Noninferiorit y will be declared if the lower bound of the 2 -sided 95% CIfor the GMR of 
lyophilized SDV relative to the corresponding frozen -liquid MDV control is greater than 
0.67 (1.5-fold criterion).
9.1.3. Multiplicity Considerations
There is onl y 1hypothesis fortheprimary  immunogenicity  endpoint, and within -group 
descriptive summaries will be provided for the secondary  immunogenicity  endpoint.   
Consequently ,no multiplicity  adjustment s areapplied .
9.2.Sample Size Determination
The sample size in Part 1 
of the study is based on the noninferiorit y evaluation for the 
primary  immunogenicity  endpoint, full -length S -binding IgG levels 1 month after Dose 2, 
using a 1.5 -fold noninferiority  margin for the comparison between ly ophilized S DV 
BNT162b2 relative to frozen- liquid MDV BNT162b2. The second part of the study for 
assessing the 
immu ne responses induced by  frozen - liquid BNT162b2 with LNP size at the 
upper end of specification orRTU BNT162b2 isfordescriptive purpose s;thus, sample size 
for this part is not based on statistical consideration s.
Common assay  standard deviations from each group are assumed to be 0.6456 based on 
results from Phase 1 of Study C4591001 (BNT162b2 30 µg , 18- to 55 -year age group). With 
th
isstandard deviation and the observed GMT difference assumed in the power analy sis 
below, a sample size of 220evaluable participants per group in Part 1 of the study  will 
provide a power of 9 0.1% to 
decla renoninferiority of lyophilized BNT162b2 to frozen -liquid 
MDVfor the primary  objective (Table4).
Assuming a nonevaluable rate of 20%, the stud y will randomize approximately  
275participants toeach group in Part 1 
of the study  to achieve the required number of 
evaluable participants.
Table4. Power Analysis for Noninferiority Assessment
Criteria Standard Deviation 
(Log Value)aAssu med Observed 
GMT Difference 
(Log Scale)Number of Evaluable 
Participants per 
GroupPowerb
Lower limit of 95% CI for 
GMR ( lyophilized SDV 
BNT162b2 /frozen -liquid 
MDV BNT162b2 ) >0.670.6456 -0.2 220 90.1%
Abbreviation s: GMR = geometric mean ratio ; GMT= geometric mean titer; MDV = multidose vial; 
SDV = single -dose vial .
a.Reference: BNT162b2 (30 µg), 18 -to 55 -year age group (C4591001 Phase 1, N=12).  Calculation may be 
updated if additional information becomes available to better estimate the standard deviation.
b.At the 0.05 alpha level (2 -sided).

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 669.3.Analysis Sets
For purposes of analy sis, the following anal ysis sets are defined:
Participant Analysis Set Description
Enrolled All participants who have a signed ICD .
Randomized All participants who are assigned a randomization number in 
the IWR sy stem.
Evaluable immunogenicity All eligible randomized participants who receive 2 doses of 
the vaccine to which they are randomized with Dose 2 
received within the predefined window, have at least 1 valid 
and determinate immunogenicity  result from the blood sample 
collected within an appropriate window at 1 month after the 
Dose 2 visit, are negative for SARS -CoV -2 infection during 
the study , and have no other important protocol deviations as 
determined b y the clinician.
Dose 3 evaluable 
immunogenicit yAll eligible randomized participants who receive 2 doses of 
lyophilized formulation of BNT162b2 to which they  are 
randomized, with Dose 2 received within the predefined 
window, receive a third dose of frozen- liquid BNT162b2 
formulation, have at least 1 valid and determinate 
immunogenicit y result from the blood sample collected within 
an appropriate window at the 1- month post –Dose 3visit, are 
negative for SARS -CoV -2 infection during the study , and 
have no other important protocol deviations as determined by  
the clinician.
All-available 
immunogenicit yAll participants who receive at least 1 dose of t he study  
intervention and have at least 1 valid and determinate 
immunogenicit y result after vaccination.
Safety All randomized participants who receive at least 1 dose of the 
study  intervention.
9.4. Statistical Analyses
The SAP will be developed and finalized before any  anal yses are performed and will 
describe the anal yses and procedures for accounting for missing, unused, and spurious data.  
This section is a summary of the planned statistical analy ses of the primary  and secondary  
endpoints.
9.4.1. General Considerations
Unless stated otherwise, “vaccine group” in this section refers to participants receiving 
lyophilized SDV , frozen- liquid MDV control for lyophilized SDV, frozen- liquid BNT162b2 
with L NP size at the upper end of specification ,or RTU BNT162b2 .  CIs for all endpoints in 

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 67the statistical analy sis will be presented as 2-sided at the 95% level unless specified 
otherwise.
For all the immunogenicity  endpoints, the analy sis will be based on the evaluable 
immunogenicit y population or Dose 3 evaluable i mmunogenicit y population .An additional 
analysis will be performed based on the all -available immunogenicit y population if there is a 
large enough difference in sample size between the all -available immunogenicity  population 
and the evaluable immunogenici ty population.  Participants will be summarized according to 
the vaccine group to which they  were randomized.
The safet y analyses will be based on the safet y population.  Participants will be summarized 
by vaccine group according to the study  intervention sthey actuall y received.
9.4.1.1.
Analysis for Binary Data
Descriptive statistics for categorical variables (eg, proportions) are the percentage (%), the 
numerator (n) and the denominator (N) used in the percentage calculation, and the 95% CIs 
where applicable.
Theexact 95% CI for binary endpoints for each group will be computed using the 
Fdistribution (Clopper -Pearson).
9.4.1.2. Analysis for Continuous Data
Unless otherwise stated, descriptive statistics for continuous variables are n, mean, median, 
standard deviation, minimum, and maximum.
9.4.1.2.1. Geometric Mean Ratios
The GMRs will be calculated as the mean of the difference of logarithmically  transformed 
assay  results between 2 vaccine groups and exponentiating the mean.  Two -sided CI s will be 
obtained by  calculating CI s usin g Student’s t -distribution for the mean difference of the 
logarithmicall y transformed assay  results and exponentiating the confidence limits.
9.4.1.2.2. Geometric Means
The geometric means will be calculated as the mean of the assay  results after making the 
logarithm ictransformation and then exponentiating the mean to express results on the 
original scale.  Two -sided 95% CI s will be obtained by taking log transforms of assay  results, 
calculating the 95% CI with reference to Student’s t- distribution, and then exponent iating the 
confidence limits.
9.4.1.2.3. Geometric Mean Fold Rises
GMFRs are defined as ratios of the results after vaccination to the results before vaccination.  
GMFRs are limited to participants with nonmissing values at both time points.
GMFRs will be calculated as the mean of the difference of logarithmicall y transformed assay  
results (later time point minus earlier time point) and exponentiating the mean.  The 
associated 2- sided 95% CI s will be obtained b y constructing CIs using Student’s 

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 68t-distribution for the mean difference on the logarithm scale and exponentiating the 
confidence limits.
9.4.1.2.4. Reverse Cumulative Distribution Curve
Empirical RCDCs will plot proportions of participants with values equal to or exceeding a 
specified assay  value versus the indicated assa y value, for all observed assay values.  Data 
points will be joined by  a step function with data points on the left side of the step.
9.4.2. Primary Endpoint(s)
Endpoint Statistical Analysis Methods
Immunogenicity GMR of full -length S -binding IgG levels in parti cipants receiving lyophilized 
SDV BNT162b2 com pared to frozen -liquid MDV BNT162b2 control for 
lyophi lized SDV
For full -length S -binding IgG levels, the GMR at 1 month after Dose 2 w ill be 
provided along w ith associated 2 -sided 95% CIs ( see Section 9.4.1.2.1 ).
Noninferiority will be declared if the lower limit of the 2-sided 95% CI for the GMR 
is greater than 0.67 .
Safety Descriptive statistics will be provided for each reactogenicity endpoint for each dose 
and vaccine group.  Local reactions and systemic events from Day 1 through Day 7 
after each vaccination (where Day 1 is the day of vaccination) will be presented by 
severity and cumulatively across severity levels.  Descriptive summary statistics will 
include counts and percentages of participants with the indicated endpoint and the 
associated Clopper -Pearson 95% CIs (see Section 9.4.1.1 ).
AEs and SAEs will be categorized according to MedDRA terms.  Counts, 
percentages, and the associated Clopper -Pearson 95% CIs of AEs and SAEs from 
Dose 1 through 1 month after Dose 2 will be provided for each vaccine group .
9.4.3. Secondary Endpoint(s)
Endpoint Statistical Analysis Methods
Immunogenicity GMCs of full -length S -binding IgG levels
For full -length S -binding IgG levels, GMCs and 2 -sided 95% CIs will be provided for 
each vaccine group in Part 1 of the study (lyophilized BNT162b2 in SDVs and 
frozen -liquid BNT162b2 in MDVs )at baseline (before Dose 1) and at 1 month after 
Dose 2.
Statistical methods are described in Section 9.4.1.2.2 .
GMFRs of full-length S -binding IgG levels
For full -length S -binding IgG levels, the GMFRs and 2 -sided 95% CIs w ill be 
provided for each vaccine group in Part 1 of the study (lyophilized BNT162b2 in 
SDVs and frozen -liquid BNT162b2 in MDVs) from baseline (before Dose 1) to
1month after Dose 2.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 69Endpoint Statistical Analysis Methods
GMFR s will be limited to participants with nonmissing values prior to the first dose 
and at the postvaccination time point. The statistical methods are described in 
Section 9.4.1.2.3 .
9.4.4. Exploratory Endpoint(s)
Endpoint Statistical Analysis Methods
Safety Descriptive statistics will be provided for each reactogenicity endpoint in participants 
who originally received 2 doses of lyophilized formulation of BNT162b2 and 
received frozen -liquid BNT162b2 formulation as a third dose. Local reactions and 
systemic events from Day 1 through Day 7 after the third dose (where Day 1 is the 
day of the third dose ) will be presented by severity and cumulatively across severity 
levels. Descriptive summary statistics will include counts and percentages of 
participants with the indicated endpoint and the associated Clopper -Pearson 95% CIs 
(see Section 9.4.1.1 ).
AEs and SAEs will be categorized according to MedDRA terms. Counts and
percentages of participants with AEs and SAEs from Dose 3through 1 month after 
Dose 3will be provided ,along with the associated Clopper -Pearson 95% CIs .
Immunogenicity GMRof frozen -liquid BNT162b2 with LNP size at the upper end of specification
relative to frozen -liquid BNT162b2 in MDVs at 1 m onth after Dose 2
For full -length S -binding IgG levels and/or SARS -CoV- 2 neutralizing titers , the GMR 
at 1 month after Dose 2 will be provided along w ith associated 2 -sided 95% CIs (see 
Section 9.4.1.2.1 ).For the analysis of full -length S -binding IgG levels, all available 
IgG data for participants receiving frozen -liquid BNT162b2 in MDVs from Part 1 w ill 
be used. For the analysis of SARS -CoV -2 neutralizing titers, a random sample of 
approximately 30 age-match edparticipants receiving frozen -liquid BNT162b2 in 
MDVs will be selected from Part 1 of the study.
GMCs of full -length S -binding IgG levels and/or GMTs of SARS -CoV -2
neutralizing titers
For full -length S -binding IgG levels and/or SARS -CoV- 2 neutralizing titers , 
GMCs /GMTs and 2 -sided 95% CIs will be provided for each vaccine group in Part 2 
of the study (frozen -liquid BNT162b2 w ith LNP size at the upper end of specification 
and RTU formulation )at baseline (before Dose 1) and at 1 month after Dose 2.
Statistical methods are described in Section 9.4.1.2.2 .
GMFRs of full-length S -binding IgG levels and/or SARS -CoV -2 neutralizing 
titers
For full -length S -binding IgG levels, the GMFRs and 2 -sided 95% CIs w ill be 
provided for each vaccine group in Part 2 of the study (frozen -liquid BNT162b2 w ith 
LNP size at the upper end of specification and RTU formulation ) from baseline 
(before Dose 1) t o1 month after Dose 2.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 70Endpoint Statistical Analysis Methods
GMFRs will be limited to participants with nonmissing values prior to the first dose 
and at the postvaccination time point. The statistical methods are described in 
Section 9.4.1.2.3 .
GMCs of full -length S -binding IgG levels and/or GMTs of SARS -CoV -2 
neutralizing titers for participants receiving the third dose
For full -length S -binding IgG levels and/or SARS -CoV- 2 neutralizing titers, 
GMCs/GMTs and 2 -sided 95% CIs will be provided for Dose 3 evaluable 
immunogenicity participants at baseline (before Dose 1) , 1 mo nth after Dose 2, prior 
toDose 3 ,and 1month after Dose 3.
Statistical methods are described in Section 9.4.1.2.2 .
GMFRs of full-length S -binding IgG levels and/or SARS -CoV -2 neutralizing 
titers for participants receiving the third dose
For full -length S -binding IgG levels and/or SARS -CoV- 2 neutralizing titers , the 
GMFRs from prior toDose 3 to 1 month after Dose 3 and 2 -sided 95% CIs w ill be 
provided for participants receiving the third dose.
GMFRs will be limited to participants with nonmissing values prior to Dose 3 and at 
1 month after Dose 3 .The statistical methods are described in Section 9.4.1.2.3 .
9.5.Interim Analyses
No formal interim anal ysis will be conducted for this study .Statistical analy ses will be 
carried out when the final data for specified objectives for a given study  part are available 
while the study  is ongoing.
9.6.Data Monitoring Committee or Other Independent Oversight Committee
This study  will use a DMC.  The DMC is independent of the study team and includes 
external members.   The DMC charter describes the role of the DMC in more detail.
The DMC will be responsible for ongoing monitoring of the safety  of participants in the 
study  according to the charter.  This may  include, but is not limited to:
Contemporaneous review of related AEs up to 1 month after completion of the 
vaccination schedule,
Contemporaneous review of all SAEs up to 1 month after completion of the 
vaccination schedule.
The recommendations ma de by the DMC to alter the conduct of the stud y will be forwarded 
to the appropriate Pfizer personnel for final decision.  Pfizer will forward such decisions, 
which may  include summaries of aggregate analy ses of safety  data, to regulatory  authorities, 
as appropriate.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 7110.SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in accordance with the protocol and with the following:
Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and CI OMS International Ethical Guidelines ;
Applicable ICH GCP guidelines;
Applicable laws and regulations , including applicable privacy  laws.
The protocol, protocol amendments, I CD, SRSD(s) , and other relevant documents 
(eg,advertisements) must be 
reviewed and approved by  the sponsor and submitted to an 
IRB/EC by  the investigator and reviewed and approved by  the IRB/EC before the study  is 
initiated.
Any amendments to the protocol will require IRB/EC approval before implementation of 
changes made to the study design, except for changes necessary  to eliminate an immediate 
hazard to study  participants.
The investigator will be responsible for th e following:
Providing written summaries of the status of the study  to the IRB/EC annually  or 
more frequently  in accordance with the requirements, policies, and procedures 
established by  the IRB/EC ;
Notify ing the IRB/EC of SAEs or other significant safet y findings as required by  
IRB/EC procedures;
Providing oversight of the conduct of the stud y at the site and adherence to 
requirements of 21 CFR, ICH guidelines, the IRB/EC, European regulation 536/2014 
for clinical studies (if applicable), and all other app licable local regulations .
10.1.1.1. Reporting of Safety Issues and Serious Brea ches of the Protocol or ICH GCP
In the event of an y prohibition or restriction imposed (ie, clinical hold) b y an applicable 
regulatory  authority in any area of the world, or if the inves tigator is aware of an y new 
information that might influence the evaluation of the benefits and risks of the study  
intervention , Pfizer should be informed immediately .
In addition, the investigator will inform Pfizer immediately  of any  urgent safet y measur es 
taken b y the investigator to protect the study participants against an y immediate hazard, and 
of an y serious breaches of this protocol or of ICH GCP that the investigator becomes aware 
of.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 7210.1.2. Financial Disclosure
Investigators and subinvestigators will provide the sponsor with sufficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory  authorities.  I nvestigators 
are responsible for providing information on financial interests during the course of the stud y 
and for 1 year after completion of the study .
10.1.3. Informed Consent Process
The investigator or his/her representative will explain the nature of the study to the 
participant and a nswer all questions regarding the study .  The participant should be given 
sufficient time and opportunity  to ask questions and to decide whether or not to participate in 
the trial.
Participants must be informed that their participation is voluntary .Parti cipants will be 
required to sign a statement of informed consent that meets the requirements of 21 CFR 50, 
local regulations, ICH guidelines, HI
PAA requirements, where applicable, and the IRB/EC 
or study  center.
The investigator must ensure that each study participant is fully  informed about the nature 
and objectives of the study, the sharing of data related to the study ,and possible risks 
associated with participation, including the risks associated with the processing of the 
participant ’s personal data.
The participant must be informed that his/her personal study -related data will be used by  the 
sponsor in accordance with local data protection law. The level of disclosure must also be 
explained to the participant.
The participant must be informed that hi s/her medical records may  be examined by  Clinical 
Quality  Assurance auditors or other authorized personnel appointed by  the sponsor, by  
appropriate IRB/EC members, and b y inspectors from regulatory authorities.
The investigator further must ensure that eac h study  participant is fully  informed about his or 
her right to access and correct his or her personal data and to withdraw consent for the 
processing of his or her personal data.
The medical record must include a statement that written informed consent wa s obtained 
before the participant was enrolled in the study
 and the date the written consent was obtained.
The authorized person obtaining the informed consent must also sign the IC D.
Participants must be reconsented to the most current version of the IC D(s) during their 
participation in the study .
A cop y of the ICD(s) must be provided to the participant.  Participants who are rescreened 
are required to sign a new I CD.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 73Unless prohibited by local requirements or IRB/EC decision, the I CD will contain a separ ate 
section that addresses the use of samples for optional additional research.  The optional 
additional research does not require the collection of an y further samples.  The investigator 
or authorized designee will explain to each participant the objectiv es of the additional 
research.  Participants will be told that they  are free to refuse to participate and may  
withdraw their consent at any  time and for any  reason during the storage period.
10.1.4. Data Protection
All parties will comply  with all applicable laws, including laws regarding the implementation 
of organizational and technical measures to ensure protection of participant data.
Participants’ personal data will be stored at the study  site in encry pted electronic and/or paper 
form and will be password prot ected or secured in a locked room to ensure that only  
authorized study  staff have access.  The study  site will implement appropriate technical and 
organizational measures to ensure that the personal data can be recovered in the event of 
disaster.  In the e vent of a potential personal data breach, the study  site will be responsible 
for determining whether a personal data breach has in fact occurred and, if so, providing 
breach notifications as required by  law.
To protect the rights and freedoms of participan tswith regard to the processing of personal 
data, participants will be assigned a single, participant -specific numerical code. Any 
participant records or data sets that are transferred to the sponsor will contain the numerical 
code; participant names will not be transferred. All other identifiable data transferred to the 
sponsor will be identified by  this single, participant- specific code. The study  site will 
maintain a confidential list of participant s who participated in the study, linking each 
participant ’s numerical code to his or her actual identity and medical record identification . In 
case of data transfer, the sponsor will protect the confidentiality  of participant s’ personal data 
consistent with the c linical study agreement and applicable privacy  laws.
10.1.5. Dissemination of Clinical Study Data
Pfizer fulfills its commitment to publicly  disclose clinical study  results through posting the 
results of studies on www.clinicaltrials.gov (ClinicalTrials.gov), the EudraCT, and/or 
www.pfizer.com, and other public registries in accordance with applicable local 
laws/regulations.  In addition, Pfizer reports study  results outside of the requirements of local 
laws/regula tions pursuant to its SOPs.
In all cases, stud y results are reported b y Pfizer in an objective, accurate, balanced, and 
complete manner and are reported regardless of the outcome of the stud y or the country in 
which the study  was conducted.
www.clinicaltri als.gov
Pfizer posts clinical trial results on www.clinicaltrials.gov for Pfizer- sponsored interventional 
studies (conducted in patients) that evaluate the safety  and/or efficacy  of a product, 
regardless of the geographical location in which the study  is conducted.  These r esults are 
submitted for posting in accordance with the format and timelines set forth by  US law.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 74EudraCT
Pfizer posts clinical trial r esults on EudraCT for Pfizer -sponsored interventional studies in 
accordance with the format and timelin es set forth by  EU requirements.
www.pfizer.com
Pfizer posts public disclosure s ynopses (CSR synopses in which an y data that could be used 
to identify  individual participants have been removed) on www.pfizer.com for 
Pfizer -sponsored interventional studies at the same time the corresponding study  results are
posted to www.clinicaltrials.gov .
Documents within marketing authorization packages/submissions
Pfizer complies with the European Union Policy  0070, the proactive publication of clinical 
data to the EMA website.  Clinical data, under Phase 1 of this policy , includes clinical 
overviews, clinical summaries, CSRs, and appendices containing the protocol and protocol 
amendments, sample CRFs, and statistical methods.  Clinical data, under Phase 2 of this 
policy , includes the publishing of individual participant data.  Policy  0070 applies to new 
marketing authorization applications submitted via the centralized procedure since 
01January 2015 and applications for line extensions and for new indications submitted via 
the centralized procedure since 01 July  2015.
Data Sharing
Pfizer provides researchers secure access to patient- level data or full CSRs for the purposes 
of “bona -fide scientific research” that contribute sto the scientific understanding of the 
disease, target, or compound class. Pfizer will make available data from these trials 
24months after study  completion.  Patient -level data will be anon ymized in accordance with 
applicable privacy  laws and regulations.  CSRs will have personall y identifiable info rmation 
redacted.
Data requests are considered from qualified researchers with the appropriate competencies to 
perform the proposed analy ses. Research teams must include a biostatistician. Data will not 
be provided to applicants with significant conflict s of interest, including individuals 
requesting access for commercial/competitive or legal purposes.
10.1.6. Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically  (eg, laboratory  data). The investigator is 
responsible for verify ing that data entries are accurate and c orrect by  physically  or 
electronically  signing the CRF.
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 75The investigator must ensure that the CRFs are securel y stored at the study site in encry pted 
electronic and/or paper form and are password protected or secured in a locked room to 
prevent access b y unauthorized third parties.
The investigator must permit study -related monitoring, audits, IRB/EC review, and 
regulatory  agency  inspections and provide direct access to source data documents.   This 
verification may  also occur after study  completion.  I t is important that the investigator(s) 
and their relevant personnel are available during the monitoring visits and possible audits or 
inspecti ons and that sufficient time is devoted to the process.
Monitoring details describing strategy  (eg, risk
-based initiatives in operations and quality  
such as risk management and mitigation strategies and analytical r isk-based monitoring), 
methods, responsibilities, and requirements, including handling of noncompliance issues and 
monitoring techniques (central, remote, or on -site monitoring) ,are provided in the
monitoring plan.
The sponsor or designee is responsible for the data management of this s tudy,including 
quality  checking of the data.
Study  monitors will perform ongoing source data verification to confirm that data entered 
into the CRF by  authorized site personnel are accurate, complete, and verifiable from source 
documents; that the safety and rights of participants are being protected; and that the study  is 
being conducted in accordance with the currently  approved protocol and any  other study  
agreements, I CH GCP, and all applicable regulatory  requirements.
Records and documents, including s igned IC Ds, pertaining to the conduct of this study  must 
be retained b y the investigator for 15years after study  completion unless local regulations or 
institutional policies require a longer retention period. No records may  be destroy ed during 
the retention period without the written approval of the sponsor. No records may  be 
transferred to another location or party without written notification to the sponsor. The 
investigator must ensure that the records continue to be stored securel y for aslong as t hey are 
maintained.
When participant data are to be deleted, the investigator will ensure that all copies of such 
data are promptly  and irrevocabl y deleted from all systems.
The investigator(s) will notify thesponsor or its agents immediately  of any  regul atory  
inspection notification in relation to the study .  Furthermore, the investigator will cooperate 
with the sponsor or its agents to prepare the investigator site for the inspection and will allow 
the sponsor or its agent, whenever feasible, to be prese nt during the inspection.  The 
investigator site and investigator will promptly  resolve any  discrepancies that are identified 
between the stud y data and the participant's medical records.  The investigator will promptly  
provide copies of the inspection fin dings to the sponsor or its agent.  Before response 
submission to the regulatory  authorities, the investigator will provide the sponsor or its 
agents with an opportunity to review and comment on responses to an y such findings.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 7610.1.7. Source Documents
Source docum ents provide evidence for the existence of the participant and substantiate the 
integrit y of the data collected. Source document s are filed at the investigator site.
Data reported on the CRF or entered in the eCRF that are from source documents must be 
consistent with the source documents or the discrepancies must be explained . The 
investigator may  need to request previous medical records or transfer records, depending on 
the study . Also, current medical records must be available.
Definition of what co nstitutes source data can be found in the study monitoring plan .
Description of the use of computerized sy stem is documented in the data management plan.
10.1.8. Study and Site Start and Closure
The study  start date is the date on which the clinical study  will be open for recruitment of 
participants.
The first act of recruitment is the date of the first participant’s first visit and will be the study  
start date.
The sponsor designee reserves the right to close the study  site or terminate the study  at any  
time for a ny reason at the sole discretion of the sponsor. Study  sites will be closed upon 
study  completion. A study  site is considered closed when all required documents and study  
supplies have been collected and a stud y-site closure visit has been performed.
Theinvestigator may initiate study -site closure at any  time upon notification to the sponsor 
or designee if requested to do so by  the responsible I RB/EC or if such termination is required 
to protect the health of study  participants .
Reasons for the earl y closure of a stud y site b y the sponsor may include but are not limited 
to:
Failure of the investigator to comply  with the protocol, the requirements of the 
IRB/EC or local health authorities, the sponsor's procedures, or GCP guidelines;
Inadequate recruitm ent of participants by  the investigator;
Discontinuation of further study  intervention development .
If the stud y is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators, the ECs/IRBs, the regulatory  authorities, and any  CRO (s) used in the study  of 
the reason for termination or suspension, as specified by  the applicable regulatory  
requirements. The investigator shall promptly  inform the participant and should assure 
appropriate 
participant therapy  and/or follow -up.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 77Study  termination is also provided for in the clinical study  agreement.  If there is any  conflict 
between the contract and this protocol
,the contract will control as to termination rights.
10.1.9. Publication Policy
The results of this study  may  be published or present ed at scientific meetings b y the 
investigator after publication of the overall study  results or 1 y ear after the end of the study  
(or study  termination), whichever comes first.
The investigator agrees to refer to the primary  publication in any  subsequent p ublications 
such as secondary  manuscripts, and submits all manuscripts or abstracts to the sponsor 
30days before submission.  This allows the sponsor to protect proprietary  information and to 
provide comments and the investigator will, on request, remove any previously  undisclosed 
confidential information before disclosure, except for an y stud y-or Pfizer intervention -
related information necessary  for the appropriate scientific presentation or understanding of 
the study  results.
For all publications relati ng to the stud y, the investigator will compl y with recognized ethical 
standards concerning publications and authorship, including those established by  the 
International Committee of Medical Journal Editors.
The sponsor will comply  with the requirements for publication of the overall study  results 
covering all investigator sites.  I n accordance with standard editorial and ethical practice, the 
sponsor will support publication of multicenter studies only  in their entirety and not as 
individual site data.  I n this case, a coordinating investigator will be designated by  mutual 
agreement.
Authorship of publications for the overall study  results will be determined by  mutual 
agreement and in line with I nternational Committee of Medical Journal Editors authorship 
requirements.
If publication is addressed in the clinical study  agreement, the publication policy  set out in 
this section will not apply.
10.1.10.
Sponsor’s Qualified Medical Personnel
The contact information for the sponsor's appropriately  qualified medical personnel for the 
study  is documented in the study  contact list located in the supporting study  documentation
or other electronic s ystem.
To facilitate access to appropriatel y qualified medical personnel on stud y-related medical 
questions or problems, participant s are provided with a contact card at the time of informed 
consent .  The contact card contains, at a minimum, protocol and study  intervention
identifiers, participant numbers, contact information for the investigator site, and contact 
details for a contact center in the event that the investigator site staff cannot be reached to 
provide advice on a medical question or problem originating from another healthcare 
professional not involved in the participant ’s participation in the study .  The contact nu mber 
can also be used b y investigator staff if they are seeking advice on medical questions or 

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 78problems; however, it should be used only in the event that the established communication 
pathway s between the investigator site and the study  team are not avail able.  I t is therefore 
intended to augment, but not replace, the established communication pathway s between the 
investigator site and the study  team for advice on medical questions or problems that may  
arise during the stud y.  The contact number is not int ended for use b y the participant directl y, 
and if a participant calls that number, he or she will be directed back to the investigator site.
10.2. Appendix 2: Clinical Laboratory Tests
A pregnancy  test will be performed at times defined in the SoA section of this protocol: Visit 
1 (Vaccination 1/Day  1) and Visit 2 (Vaccination 2/19 -23 day s after Visit 1) as well as at 
Visit 101 for participants receiving Dose 3.
Pregnancy  test (β -hCG): Local urine testing will be standard for the protocol u nless 
serum testing is required by  local regulation or IRB/EC for female participants of 
childbearing potential.
Unscheduled clinical laboratory  measurements may  be obtained at any  time during the study  
to assess an y perceived safet y issues.  Investigators must document their review of each 
laboratory  safet y report.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 7910.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
10.3.1. Definition of AE
AE Definition
An AE is an y untoward medical occurrence in a patient or clinical study  participant, 
temporally associated with the use of study  intervention, whether or not considered 
related to the stud y intervention.
NOTE: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding ), symptom, or disease (new or exacerbated) temporally  
associated with the use of study  intervention.
Events Meeting the AE Definition
Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis) 
or other safet y assessments (eg, ECG, radiological scans, vital sign measurements), 
including those that worsen from baseline, considered clinicall y significant in the 
medical and scientific judgment of the investigator   Any abnormal laboratory test 
results that meet an y of the conditions below must be recorded as an AE:
Is associated with accompany ing s ymptoms
.
Requires additional diagnostic testing or medical/surgical intervention .
Leads to a change in study  dosing (outside of any  protocol -specified dose 
adjustments) or discontinuation f rom the study , significant additional 
concomitant drug treatment, or other therap y.
Exacerbation of a chronic or intermittent preexisting condition including either an 
increase in frequency  and/or intensity  of the condition.
New conditions detected or diag nosed after study  intervention administration even 
though it may  have been present before the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overd ose of either study  
intervention or a concomitant medication. Overdose per se will not be reported as 
an AE/SAE unless it is an intentional overdose taken with possible 
suicidal/self-harming intent. Such overdoses should be reported regardless of 
sequela e.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 80Events NOT Meeting the AE Definition
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments which are associated with the underl ying disease, unless judged by  the 
investigator to be more severe than expected for the participant’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms of 
the disease/disorder being studied, unless more severe than expected for the 
participant’s condition.
Medical or surgical procedure (eg, endoscop y, appendectom y): the condition that 
leads to the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital).
Anticipated day -to-day fluctuations of preexisting disease(s) or co ndition(s) present 
or detected at the start of the study that do not worsen.
10.3.2. Definition of SAE
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met (eg, hospitalization for signs/symptoms of the disease under study , death 
due to progression of disease).
An SAE is defined as any untoward medical occurrence that, at any dose:
a.Results in death
b.Is life -threatening
The term “life-threatening ”in the definition of “serious” refers to an event in which the 
participant was at risk of death at the time of the event. It does not refer to an event that
hypothetically  might have caused death if it were more severe.
c.Requires inpatient hospitalization or prolongation of existing hospitalization
In general, hospitalization signifies that the participant has been detained (usually involving 
at least an overnight stay) at the hospital or emergency  ward for observation and/or 
treatment that would not have been appropriate in the phy sician’s office or outpatient 
setting.  Complications that occur during hospitalization are AEs.   If a complication 
prolongs hospitalization or fulfills any  other serious criteria, the event is serious. When in 
doubt as to whether “hospitalization” occurred or was necessary , the AE should be 
considered serious.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 81Hospitalization for elective treatment of a preexisting condition that did not worsen from 
baseline is not considered an AE.
d.Results in persistent disability/incapacity
The term disability  means a su bstantial disruption of a person’s ability  to conduct 
normal life functions.
This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
and accident al trauma (eg, sprained ankle) which may  interfere with or prevent 
every day life functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
f.Other situations:
Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that 
may not be immediatel y life-threatening or result in death or hospitalization but may  
jeopardize the participant or may  require medical or surgical inte rvention to prevent 
one of the other outcomes listed in the above definition. These events should 
usually  be considered serious.
Examples of such events include invasive or malignant cancers, intensive treatment 
in an emergency  room or at home for allergi c bronchospasm, blood dy scrasias or 
convulsions that do not result in hospitalization, or development of drug dependency  
or drug abuse.
Suspected transmission via a Pfizer product of an infectious agent, pathogenic or 
non-pathogenic, is considered serious.  The event may  be suspected from clinical 
symptoms or laboratory  findings indicating an infection in a patient exposed to a 
Pfizer product.  The terms “suspected transmission” and “transmission” are 
considered s ynon ymous.  These cases are considered unexp
ected and handled as 
serious expedited cases by pharmacovigilance personnel.  Such cases are also 
considered for reporting as product defects, if appropriate.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 8210.3.3. Recording/Reporting and Follow -up of AE sand/or SAE s
AE and SAE Recording /Reporting
The table below summarizes the requirements for recording adverse events on the CRF and 
for reporting serious adverse events on the Vaccine SAE Report ingForm to Pfizer Safety .  
These requirements are delineated for 3 types of events: (1) SAEs; (2) nonseri ous adverse 
events (AEs); and (3) exposure to the study  intervention under study  during pregnancy  or 
breastfeeding, and occupational exposure.
It should be noted that the Vaccine SAE Report ingForm for reporting of SAE information 
is not the same as the AE page of the CRF.  When the same data are collected, the forms 
must be completed in a consistent manner.  AEs should be recorded using concise medical 
terminology  and the same AE term should be used on both the CRF and the Vaccine SAE 
Report ingForm for re porting of SAE information.
Safety Event Recorded on the CRF Reported on the Vaccine
SAE Report ingForm to 
Pfizer Safety Within 24 
Hours of Awareness
SAE All All
Nonserious AE All None
Exposure to the study  
intervention under stud y 
during pregnancy  or 
breastfeeding, and 
occupational exposureAll AEs/SAEs associated 
with exposure during 
pregnancy  or breastfeeding
Occupational exposure is not 
recorded.All (and EDP supplemental 
form for EDP)
Note:  I nclude all SAEs 
associated with exposure 
during pregnancy  or 
breastfeeding. Include all 
AEs/SAEs associated with 
occupational exposure.
When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (eg, hospital progress notes, laboratory  reports, and diagnostic 
reports) related to the event.
The investigator will then record all relevant AE/SAE information in the CRF.
It is notacceptable for the investigator to send photocopies of the participant’s 
medical reco rds to Pfizer Safety  in lieu of completion of the Vaccine SAE Report ing
Form /AE/SAE CRF page.
There may  be instances when copies of medical records for certain cases are 
requested b y Pfizer Safety . In this case, all participant identifiers, with the 

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 83exception of the participant number, will be redacted on the copies of the medical 
records before submission to Pfizer Safety .
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. When ever possible, the diagnosis (not 
the individual signs/sy mptoms) will be documented as the AE/SAE.
Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported during 
the study  and assign it to 1 of the following categories:
GRADE If required on the AE page of the CRF, the investigator will use the 
adjectives MILD, MODERATE, SEVERE, or LIFE- THREATENING to 
describe the maximum intensity  of the AE. For purposes of consistency , 
these intensity grades are d efined as follows:
1 MILD Does not interfere with participant 's usual 
function.
2 MODERATE Interferes to some extent with participant 's usual 
function.
3 SEVERE Interferes significantl y with participant 's usual 
function.
4 LIFE -THREATENING Life-threatening consequences; urgent 
intervention indicated.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 84Assessment of Causality
The investigator is obligated to assess the relationship between stud y intervention 
and each occurrence of each AE/SAE.
A “reasonable possibility” of a relationship convey s that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.
The investigator will use clinical judgment to determine the relationship.
Alternative causes, such as underl ying disease(s), concomitant therap y, and other 
risk factors, as well as the temporal relationship of the event to study  intervention 
administration, will be considered and investigated.
The investigator will also consult the IB and/or product i nformation, for mar keted 
products, in his/her assessment.
For each AE/SAE, the investigator must document in the medical notes that he/she 
has reviewed the AE/SAE and has provided an assessment of causality .
There may  be situations in which an SAE has occurred and the invest igator has 
minimal information to include in the initial report to the sponsor. However, it is 
very important that the investigator always make an assessment of causality for 
every event before the initial transmission of the SAE data to the sponsor .
The investigator may  change his/her opinion of causality  in light of follow -up 
information and send a nSAE follow -up report with the updated causality  
assessment.
The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements.
If the investigator does not know whether or not the study  intervention caused the 
event, then the event will be handled as “related to study  intervention ” for reporting 
purposes, as defined b y the sponsor .  In addition, if the investigator d etermines that 
an SAE is associated with study  procedures, the investigator must record this causal 
relationship in the source documents and CRF, and report such an assessment in the 
dedicated section of the Vaccine SAE Report ingForm and in accordance wit h the 
SAE reporting requirements.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 85Follow -up of AEs and SAEs
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically  indicated or as requested by  the 
sponsor to elucidate the nature and/or causalit y of the AE or SAE as fully as 
possible. This may  include additional laboratory  tests or investigations, 
histopathological examinations, or consultation with other healthcare providers .
If a participant dies during participation in the study  or during a recognized 
follow -up period, the investigator will provide Pfizer Safet y with a cop y of any 
postmortem findings including histopathology .
New or updated information will be recorded in the originally  completed CRF.
The investigator will submit any  updated SAE data to the sponsor within 24 hours of 
receipt of the information.
10.3.4. Reporting of SAEs
SAE Reporting to Pfizer Safety via Vaccine SAE Report ingForm
Facsimile transmission of the Vaccine SAE Report ingForm is the preferred method 
to transmit this information to Pfizer Safety .
In circumstances when the fac simile is not working , notification by  telephone is 
acceptable with a cop y of the Vaccine SAE Report ingForm sent b y overnight mail 
or courier service.
Initial notification via telephone does not replace the need for the investigator to 
complete and sign the Vaccine SAE Report ingForm pages within the designated 
reporting time frames.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 8610.4. Appendix 4: Contraceptive Guidance 
10.4.1. Male Participant Reproductive Inclusion Criteria
Male participants are eligible to participate if they  agree to the following requirements during 
the intervention period and for at least 28daysafter the last dose of stud y intervention, which 
corresponds to the time needed to eliminate reproductive safet y risk of the study  
intervention(s) :
Refrain from donating sperm.
PLUS either :
Be abstinent from heterosexual intercourse with a female of childbearing potential as 
their preferred and usual lifesty le (abstinent on a long -term and persistent basis) and 
agree to remain abstinent .
OR
Must agree to use a male condom when engaging in any  activity  that allows for 
passage of ejaculate to another person .
In addition to male condom use, a highl y effective method of contra ception may  be 
considered in WOCBP partners of male participants (refer to the 
list of highly  
effective methods below in Section 10.4.4 ).
10.4.2. Female Participant Reproductive Inclusion Criteria
A female participant is eligible to participate if she is not pregnant or breastfeeding, and at 
least 1 of the following conditions applies:
Is not a WOCBP (see definitions below in Section 10.4.3).
OR
Is a WOCBP and using an acceptable contraceptive method as described below 
during the intervention period (for a minimum of 28 day s after the last dose of study  
intervention) .  The investigator should evaluate the effectiveness of the contraceptive 
method in relationship to the first dose of stud y intervention
.
The investigator is responsible for review of medical history , menstrual history , and recent 
sexual activity  to decrease the risk for inclusion of a woman with an earl y undetected 
pregnancy .

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 8710.4.3. Woman of Childbearing Potential
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanentl y sterile (see below).
If fertility  is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cy cle cannot 
be confirmed before the first dose of study  intervention, additional evaluation should be 
considered.
Women in the foll owing categories are not considered WOCBP:
1.Premenopausal female with 1 of the following:
Documented h ysterectomy ;
Documented bilateral salpingectomy ;
Documented bilateral oophorectom y.
For individuals with permanent infertility  due to an alternate medical cause other than the 
above, (eg, mullerian agenesis, androgen insensitivity ), investigator discretion should be 
applied to determining study  entry .
Note: Documentation for any of the above categories can come from the site personnel’s 
review of the partici pant’s medical records, medical examination, or medical history  
interview.  The method of documentation should be recorded in the participant’s medical 
record for the stud y.
2.Postmenopausal female :
A postmenopausal state is defined as no menses for 12 month s without an alternative 
medical cause. In addition, a
high FSH level in the postmenopausal range must be used to confirm a 
postmenopausal state in women under 60 years of age and not using hormonal 
contraception or HRT.
Female on HRT and whose menopausal status is in doubt will be required to use 
one of the nonestrogen hormonal highl y effective contraception methods if they 
wish to continue their HRT during the stud y.  Otherwise, they  must discontinue 
HRT to allow confirmation of postmenopausal status bef ore stud y enrollment.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 8810.4.4. Contracepti onMethods
Contraceptive use b y men or women should be consistent with local availability /regulations 
regarding the use of contraceptive methods for those participating in clinical trials.
1.Implantable progestogen -only hormone contraception associated with inhibition of 
ovulation
.
2.Intrauterine device .
3.Intrauterine hormone -releasing s ystem.
4.Bilateral tubal occlusion .
5.Vasectomized partner :
Vasectomized partner is a highl y effective contraceptive method provided that the 
partner is the sole sexual partner of the woman of childbearing potential and the 
absence of sperm has been confirmed. If not, an additional highly  effective method 
of contraception should be used. The s permatogenesis cy cle is approximately  
90days.
6.Comb ined (estrogen- and progestogen -containing) hormonal contraception associated 
with inhibition of ovulation :
Oral;
Intravaginal;
Transdermal ;
Injectable .
7.Progestogen -only hormone contraception associated with inhibition of ovulation :
Oral;
Injectable .
8.Sexua l abstinence :
Sexual abstinence is considered a highl y effective method only  if defined as 
refraining from heterosexual intercourse during the entire period of risk associated 
with the study  intervention.   The reliability  of sexual abstinence needs to be evaluated 
in relation to the duration of the study
 and the preferred and usual lifest yle of the 
participant.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 899.Progestogen -only oral hormonal contraception where inhibition of ovulation is not the 
primary  mode of action.
10. Male or female condom with or without spermicide .
11. Cervical cap, diaphragm, or sponge with spermicide.
12. A combination of male condom with either cervical cap, diaphragm, or sponge with 
spermicide (double -barrier methods) .

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 9010.5. Appendix 5: Liver Safety: Suggested Actions and Follow -up Assessments
Potential Cases of Drug
-Induced Liver Injury
Humans exposed to a drug who show no sign of liver injury  (as determined by  elevations in 
transaminases) are termed “tolerators,” while those who show transient liver injury , but adapt 
are termed “adaptors.”  In some participant s, transaminase elevations are a harbinger of a 
more serious potential outcome.  These participant s fail to adapt and therefore are 
"susceptible" to progressive and serious liver injury, commonl y referred to as DILI.  
Participant s who experi ence a transaminase elevation above 3 ×ULN should be monitored 
more frequently  to determine if they  are an “adaptor” or are “susceptible.”
LFTs are not required as a routine safety  monitoring procedure in this study .  However, 
should an investigator deem it necessary  to assess LFTs because a participant presents with 
clinical signs/s ymptoms, such LFT results should be managed and followed as described 
below.
In the majority  of DILI cases, elevations in AST and/or ALT precede TBili elevations 
(>2 ×ULN) b y several day s or weeks.  The increase in TBili ty pically  occurs while 
AST/AL T is/are still elevated above 3 ×ULN (ie, AST/AL T and TBili values will be 
elevated within the same lab oratory sample).  In rare instances, by  the time TBili elevations 
are detected, AST/ALT values might have decreased.  This occurrence is still regarded as a 
potential DILI.  Therefore, abnormal elevations in either AST OR ALT in addition to TBili 
that meet the criteria outlined below are considered potential DILI (assessed per Hy ’s law 
criteria) cases and should alway s be considered important medical events, even before all 
other possible causes of liver injury  have been excluded.
The threshold of laboratory  abnormalities for a potential DILI case depends on the 
participant ’s individual baseline values and underly ing conditions.  Participant s who present 
with the following laboratory  abnormalities should be evaluated further as potential DILI 
(Hy’s law) cases to definitively  determine the etiology  of the abnormal laboratory  values:
Participant s with AST/ALT and TBili baseline values within the normal range who 
subsequently  present with AST OR AL T values >3 ×ULN AND a TBili value 
>2×
ULN with no evidence of hemol ysis and an alkaline phosphatase value 
<2×ULN or not availabl e.
For participant s with baseline AST OR ALT ORTBili values above the ULN, the 
following threshold values are used in the definition mentioned above, as needed, 
depending on which values are above the ULN at baseline:
Preexisting AST or ALT baseline values above the normal range: AST or ALT 
values >2 times the baseline values AND >3 ×ULN; or >8 ×ULN (whichever is 
smaller).

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 91Preexisting values of TBili above the normal range: TBili level increased from 
baseline value b y an amount of at least 1 × ULN orif the value reaches 
>3×ULN (whichever is smaller).
Rises in AST/AL T and TBili separated b y more than a few weeks should be assessed 
individually  based on clinical judgment; any  case where uncertainty  remains as to whether it 
represents a potential Hy’s law case should be reviewed with the sponsor.
The participant should return to the investigator site and be evaluated as soon as possible, 
preferabl y within 48 hours from awareness of the abnormal results.  This evaluation should 
include laboratory  tests , detailed history, and physical assessment.
In addition to repeating measurements of AST and AL T and TBili for suspected cases of 
Hy’s law, additional laboratory  tests should include albumin, CK, direct and indirect 
bilirubin, GGT, PT/I NR, total bile acid s, 
and alkaline phosphatase.  Consideration should 
also be given to drawing a separate tube of clotted blood and an anticoagulated tube of blood 
for further testing, as needed, for further contemporaneous anal yses at the time of the 
recognized initial abno rmalities to determine etiology .  A detailed history , including relevant 
information, such as review of ethanol, acetaminophen /paracetamol (either by  itself or as a 
coformulated product in prescription or over -the-counter medications) , recreational drug, 
supplement (herbal) use and consumption, family  history , sexual history , travel history , 
history  of contact with a jaundiced person, surgery , blood transfusion, history  of liver or 
allergic disease, and potential occupational exposure to chemicals, should be collected.  
Further testing for acute hepatitis A, B, C, D, and E infection and liver imaging (eg, biliary  
tract) and collection of serum sample s for acetaminophen/paracetamol drug and/or protein 
adduct levels may be warranted.
All cases demonstrated on repeat testing as meeting the laboratory  criteria of AST/AL T and 
TBili elevation defined above should be considered potential DILI (Hy ’s law) cases if no 
other reason for the LFT abnormalities has yet been found.  
Such potential DILI (Hy’s law) 
cases are to be reported as SAEs, irrespective of availability of all the results of the 
investigations performed to determine etiology of the LFT abnormalities .
A potential DILI (Hy ’s law) case becomes a confirmed case onl y after all results of
reasonable investigations have been received and have excluded an alternative etiology .

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 9210.6. Appendix 6: Abbreviations
The following is a list of abbreviations that may  be used in the protocol.
Abbreviation Term
2019 -nCoV novel coronavirus 2019
AE adverse event
AESI adverse event of special interest
ALT alanine aminotransferase
AST aspartate aminotransferase
-hCG beta-human chorionic gonadotropin
CBER Center for Biologics Evaluation and Research
CDC Centers for Disease Control and Prevention
CFR Code of Federal Regulations
CI confidence interval
CIOMS Council for International Organizations of Medical Sciences
CK creatine kinase
CONSORT Consolidated Standards of Reporting Trials
COVID -19 coronavirus disease 2019
CRF case report form
CRO contract research organization
CRU clinical research unit
CSR clinical study  report
DILI drug-induced liver injury
DMC data monitoring committee
EC ethics committee
ECG electrocardiogram
eCRF electronic case report form
e-diary electronic diary
EDP exposure during pregnancy
EMA European Medicines Agency
EU European Union
EUA emergency  use authorization
EudraCT European Clinical Trials Database
FDA Food and Drug Administration
FSH follicle -stimulating hormone
GCP Good Clinical Practice
GGT gamma -glutamy l transferase
GMC geometric mean concentration
GMFR geometric mean fold rise
GMR geometric mean ratio
GMT geometric mean titer
HBV hepatitis B virus

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 93Abbreviation Term
HCV hepatitis C virus
HIPAA Health Insurance Portability  and Accountability  Act
HIV human immunodeficiency virus
HRT hormone replacement therap y
IB investigator’s brochure
ICD informed consent document
ICH International Council for Harmonisation
ID identification
IgG immunoglobulin G
IMP investigational medicinal product
IND investigational new drug
INR international normalized ratio
IP manual investigational product manual
IPAL Investigational Product Accountability  Log
IRB institutional review board
IRT interactive response technology
ISF investigator site file
IWR interactive Web -based response
JCVI Joint Committee on Vaccination and I mmunisation
LFT liver function test
LLOQ lower limit of quantitation
LNP lipid nanoparticle
lyo lyophilized
MDV multidose vial
MedDRA Medical Dictionary  for Regulatory  Activities
MERS Middle East respiratory  syndrome
modRNA nucleoside -modified messenger ribonucleic acid
N SARS -CoV -2 nucleoprotein
N/A not applicable
NAAT nucleic acid amplification test
NIMP noninvestigational medicinal product
P2 S SARS -CoV -2 full-length, P2 mutant, prefusion spike gl ycoprotein
PI principal investigator
PPE personal protective equipment
PT prothrombin time
PVC premature ventricular contraction/complex
RCDC reverse cumulative distribution curve
RNA ribonucleic acid
RSV respiratory  syncytial virus
RT-PCR reverse transcription– polymerase chain reaction
RTU ready-to-use

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 94Abbreviation Term
S spike protein
S1 spike protein S1 subunit
SAE serious adverse event
SAP statistical analy sis plan
SARS severe acute respiratory  syndrome
SARS -CoV -2 s evere acute respiratory  syndrome coronavirus 2
SDV single -dose vial
SSID single subject identifier
SoA schedule of activities
SOP standard operating procedure
SRSD single reference safet y document
SUSAR suspected unexpected serious adverse reaction
TBili total bilirubin
Th 1 T-helper t ype 1
UK United Kingdom
ULN upper limit of normal
US United States
VAED vaccine -associated enhanced disease
WHO World Health Organization
WOCBP woman /women of childbearing potential

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 9511.REFERENCES
1Virus Pathogen Resource (ViPR). Strain details for severe acute respiratory sy ndrome -
related coronavirus strain Wuhan- Hu-1. Available from: 
https://www.viprbrc.org/brc/viprStrainDetails.spg?ncbiAccession=MN908947&decorat
or=corona .  Accessed: 11 Aug 2020.
2Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in 
China, 2019. N Engl J Med. 2020;382(8):727-33.
3World Health Organization. Timeline: WHO's COVID -19 response . Available from: 
https://www.who.int/emergencie s/diseases/novel -coronavirus- 2019/interactive -
timeline# !. Accessed: 08 Jan 2021.
4World Health Organization. WHO Director -General's opening remarks at the media 
briefing on COVID -19.Available from: https://www.who.int/dg/speeches/detail/
who-director -general -s-opening -remarks -at-the-media -briefing -on-covid -19--- 11-march -
2020. Published: 11 Mar 2020. Accessed: 01 Apr 2020.
5COVID -19 dashboard by the Center for S ystems Science and Engineering (CSSE) at 
Johns Hopkins University.  Available from: 
https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299
423467b48e9ecf6 .Accessed
: 08Jan2021.
6Rauch S, Jasny  E, Schmidt KE, et al. 
New vaccine technologies to combat outbreak 
situations. Front I mmunol .2018;9:1963.
7Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics—developing a new class of 
drugs. Nat Rev Drug Discov .2014;13(10):759 -80.
8Polack FP, Thomas SJ, Kitchin N, 
et al. Safet y and efficacy of the BNT162b2 mRNA 
Covid -19 vaccine. N Engl J Med. 2020;383(27):2603 -15.
9Vaccines and Related Biological Products Advisory  Committee. Vaccines and Related 
Biological Products Advisory  Committee December 10, 2020, meeting: FDA Briefing 
Document Pfizer- BioNTech COVID -19 Vaccine. Silver Spring, MD: US Department of 
Health an d Human Services ,Food and Drug Administration; Dec 2020.
10Walsh EE, Frenck FW Jr, Falsey  AR, et al. Safet y and immunogenicity of two RNA -
based Covid-19 vaccine candidates. N Engl J Med. 2020; 383(25):2439- 50.DOI: 
10.1056/NEJMoa2027906.
11BioNTech RNA Pharmaceuticals GmbH. CorVAC/BNT162 i nvestigator’s brochure. 
Mainz, German y: BioNTech RNA Pharmaceuticals GmbH; 
12 Aug 2020.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C4591020
Final Protocol Amendment 2, 13Sep 2021
PFIZER CONFIDENTIAL
Page 9612US Food and Drug Administration. Guidance for industry : toxicity  grading scale for 
healthy  adult and adolescent volunteers enrolled in preventive vaccine clinical trials. 
Rockville, MD: Center for Biologics Evaluation and Research; Sep 2007.
13Centers for Disease Control and Prevention.  Symptoms of coronavirus.  Available 
from: https://www.cdc.gov/coronavirus/2019 -ncov /symptoms -testing/s ymptoms.html .  
Updated: 13 May  2020. Accessed: 20 Oct 2020.

'RFXPHQW $SSURYDO 5HFRUG
'RFXPHQW 1DPH	



	
	
'RFXPHQW 7LWOH !"#$%!"&'(&)$ !*+!,*"')+
**-*,*")&$)$*, !$##+ ". $$*,"-#+)*$)-"#+)*$" "-*'$  !$!*& *	/0.$ *"'$!	$ )*,!+)*	1*"+.,"-.
6LJQHG %\ 'DWH*07 6LJQLQJ &DSDFLW\
	((
		5	5 &46766)7
8
	((
		5	:5: -7
8PPD
PPD